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ABSTRACT 
Sandeep K. Kasoji: Early Assessment of Tumor Response to Radiation Therapy  
Using Advanced Contrast Enhanced Ultrasound Imaging Techniques and Applications for 
Prostate Cancer 
(Under the direction of Paul A. Dayton) 
 
Traditional anatomical imaging for cancer diagnosis and assessing response to therapy is 
limited to just the superficial appearance of a tumor. A functional imaging approach, which takes 
a closer at look various microenvironments within the tumor, is likely to offer a more holistic 
view of the tumor behavior and response to treatment. Acoustic Angiography is a novel super-
harmonic contrast ultrasound imaging technique that utilizes a dual-frequency transducer to 
quickly generate high-resolution 3D microvascular images with exceptionally high contrast-to-
tissue ratio. Herein, we demonstrate the ability of Acoustic Angiography to quantify tumor 
microvascular features and investigate their changes after therapeutic doses of radiation therapy 
in a tumor bearing rodent model. We then demonstrate using functional longitudinal data 
analysis that quantified microvascular features can be used to predict radiation therapy response 
with limited time point measurements. 
Prostate cancer is the most common cancer in men, resulting in near 30,000 deaths a year 
in the United States alone. Current diagnostic and staging techniques for prostate cancer have 
been shown to have low sensitivity and specificity, limiting early detection and intervention. 
There is potential for improving ultrasound imaging techniques for aiding in prostate cancer 
detection and biopsy guidance with Acoustic Angiography imaging. The clinical translation of 
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Acoustic Angiography hinges on certain design improvements, primarily increased depth of 
penetration. The last part of this dissertation discusses the development of a dual-frequency 
linear array transducer for Acoustic Angiography.  
This dissertation consists of two primary hypotheses: 
1) Acoustic Angiography can be used to quantify changes in tumor microvascular features 
and predict radiation treatment response earlier than using tumor volume alone. 
2) Acoustic Angiography using a dual-frequency linear array transducer is suitable for 
prostate cancer imaging. 
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CHAPTER 1: 
Overview of Cancer and Radiation Therapy 
 
1.1 Cancer and the Role of Angiogenesis 
It is expected that over 1.6 million new cases of cancer will be diagnosed in 2017 in the 
United States and over 12 million new cases worldwide, with an estimated number of deaths 
reaching over 600,000 and 7 million, respectively [1,2]. Cancer incidence and mortality 
increased significantly during the 20th century, most probably due to the surge in tobacco use 
and other health epidemics such as obesity, increased alcohol consumption, and poor western-
type diets. While cancer rates have slowly declined since the 1990’s with improved diagnostics, 
treatment, and healthier lifestyles, it is still the second most deadly disease in America, after 
heart disease, claiming 1 out of every 4 deaths [3].  
Advancements in cancer diagnostics have improved the early detection of specific 
cancers, allowing physicians to provide treatment at earlier stages, increasing the probability of 
controlling tumor metastasis and malignancy. Additionally, technological advancements in 
cancer therapies (i.e. nanomedicines, immunotherapies) have improved the specificity and 
efficiency for tumor control [4,5]. While advancements in healthcare over the last 50 years have 
improved cancer survival rates, cancer has remained a worldwide epidemic. 
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Cancer arises when mutations in the DNA of normal cells result in aberrant cellular 
growth and function. Mutations can be caused by both environmental factors and genetic 
disposition, however recent data has shown that most cancers arise from random DNA copying 
“mistakes” [6]. Native cellular repair mechanisms will usually fix these mutations at various 
checkpoints in the cell cycle, or the cell will undergo apoptosis to prevent further mitotic 
divisions of the abnormal cell. Defects or mistakes made in these repair mechanisms may result 
in accumulation of mutations drastically increasing the probability of cancer [7]. 
Mutated cellular DNA can lead to the deregulation of cell signal transduction pathways, 
such as RNA transcription, protein synthesis, resulting in the inactivation or overactivation of 
certain cellular processes [8]. Usually these sorts of modifications result in increased 
proliferation of the aberrant cells and unsettles the balance of regulatory pathways that maintain 
homeostasis in the body. Hanahan et al proposed six “hallmarks of cancer” consisting of 
molecular characteristics of the tumor microenvironment that contribute to the development and 
proliferation of tumors, one of which is aberrant angiogenesis. 
Normal angiogenesis is precisely regulated by the expression of pro-angiogenic and anti-
angiogenic factors. In normal tissue, the balance between the expression of both factors is shifted 
towards anti-angiogenesis resulting in mostly quiescent blood vessels [9]. Rapidly proliferating 
tumor cells will eventually become hypoxic as they grow beyond the diffusion limit of oxygen 
with the existing vascular supply, thus straining the metabolic processes of the neoplasm [10]. 
This oxygen and nutrient starvation caused by hypoxia is a major driving factor in the 
upregulation of angiogenesis, resulting in a shift towards pro-angiogenic factors [9].  
Tumor angiogenesis is characterized by aberrant, uncontrolled growth of new vasculature 
as a result of the upregulation of pro-angiogenic factors. The new growth is typically chaotic in 
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nature, resulting in excessive sprouting of disorganized, tortuous, and highly dense networks of 
vessels. While initially the newly stimulated angiogenesis increases oxygenation and nutrient 
delivery to a certain extent, the overall function of the tumor vasculature is deficient, suffering 
from leaky vessels and poor perfusion [11]. Further endothelial cell recruitment of pericytes 
ultimately results in the formation of premature vessels, as they are constantly bombarded with 
signaling factors preventing complete vessel maturation [12].   
The rate and extent of angiogenesis varies by tumor type and the microenvironment 
conditions leading to tumors with a wide range of vascularity. The extent of tumor vascularity 
has significant implications on the growth of the tumor and the effectiveness of various treatment 
modalities, specifically chemotherapy and radiotherapy (RT). Chemotherapy (targeted or 
untargeted), typically administered intravenously, requires sufficient blood flow into the tumor 
region for maximum effect. In addition to increased vascular density and tortuosity, angiogenesis 
is often accompanied with tumor hypoxia and necrosis [13]. Tumor necrosis has been reported to 
correlate with levels of angiogenesis and poor prognosis of malignant cancer. Specifically, αvβ3 
integrin, a key regulator in tumor angiogenesis is known to be associated with necrosis and 
apoptotic activity [14]. Therefore it is typical for tumors to develop necrotic and perinecrotic 
regions of the tumor. Since a higher density of vessels exist in the perimeter of the tumor, 
successfully delivering a sufficient concentration of drug throughout the entire tumor is difficult. 
New techniques that stimulate transient increased blood flow, such as “vascular promotion 
therapy”, assist in delivering the drug into the hypoxic regions of the tumor [15]. The opposing 
school of thought employs methods of reducing the tumor pro-angiogenic drive using anti-
angiogenic drugs in order to stunt tumor growth and possibly induce tumor regression [16]. 
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Usually, these techniques are used together with other treatment strategies such as radiation or 
surgical resection. 
Similarly, presence of blood as an oxygen carrier increases the efficacy of RT by 
increasing oxygen radical formation, an indirect mechanism for radiation assisted cell death. 
Microvessel density and perfusion have been shown to be a prognostic factor of RT response. 
Previous studies have demonstrated the radioresistance of hypovascular/hypoxic tumors as well 
as the improvement in RT response with pro-angiogenic pre-treatment of the tumor prior to 
radiation.  Other studies have proposed the delivery of secondary oxygen carriers via IV or 
intratumoral injection to increase oxygen concentration for increasing radiosensitivity [17].  
 
1.2 Radiation Therapy and its Effect on Tumor Microvasculature 
RT is one of the most basic forms of cancer treatment, used to treat approximately 50% 
of all cancer patients during their first course of treatment, and contributes to 40% of curative 
cancer treatment [18,19]. Approximately 40% of cancer patients are on at least their second 
course of RT, with rates of cancer resistance ranging from 20-30% for PCa, 10% for breast 
cancer, and as high as 90% for some types of lung cancer [20–23]. 
 Although ionizing radiation has been used over 110 years for treating cancer, many facets 
of radiobiology are still not well understood. The most accepted theory of the radiobiological 
mechanism for cancer treatment using conventional radiation is the direct and indirect damage 
inflicted on cellular DNA. The specific chemical mechanisms for DNA damage are still being 
studied, but in general, DNA is affected by ionizing radiation in two ways. Ionizing radiation 
(photons or atomic particles) can directly pass through cellular DNA causing base-pair deletions, 
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or single and double-strand breaks. Although direct ionization occurs, it only accounts for a 
small contribution of the total DNA damage [24]. Ionization can also pass through the cellular 
membrane, interacting with aqueous molecules and forming reactive oxygen species (ROS) and 
free radicals. ROS and free radicals are extremely reactive (given their unpaired electrons) and 
readily attack covalent bonds of DNA, causing single and double-strand breaks [25]. This 
accounts for the majority of DNA damage (>80%) and is the most commonly accepted 
mechanism for cellular death. Cellular repair mechanisms (base excision repair) deal with base-
pair deletions and single-strand breaks on a daily basis due to natural production of ROS and free 
radicals; however, repair of double-strand breaks is prone to errors and usually results in cellular 
apoptosis. Although some normal cell damage is inevitable during RT of cancer, it has been 
reported that highly proliferating cells such as cancer are more sensitive to radiation. Cellular 
death from radiation exposure occurs during the mitotic phases, therefore quickly dividing cells 
react sooner than healthy tissue [26]. The same phenomenon holds true for other quickly 
dividing cells such as epithelial and endothelial cells. 
 To date, the clinical standard for assessing radiation treatment response is a system 
similar to Response Evaluation Criteria in Solid Tumors (RECIST), where changes in tumor size 
indicate positive or negative treatment response [27]. Unfortunately, gross changes in tumor 
volume (TV) occur very slowly (weeks to months after treatment) and is a limitation especially 
when the tumor is not responding well to the treatment as early assessment of a failed treatment 
will allow physicians more time to switch treatment strategies. Advances in radiobiology over 
the last half-century had revealed that changes in TV are the result of a long cascade of intricate 
biological processes.  Better understanding the effect of radiation on various tumor 
microenvironments will enable us to further improve patient outcomes either by better and faster 
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assessment of response to therapy, improving the effectiveness of adjuvant therapies, or 
developing more advanced methods of RT. One such microenvironment, the tumor 
microvasculature, has been known to be significantly affected by radiation, resulting in a series 
of molecular changes that result in tumor cell death and control [28]. Endothelial apoptosis of 
tumor microvasculature is known to be a homeostatic factor in the regulation of tumor growth 
and is strongly correlated with tumor control when treated with radiation, therefore suggesting 
that DNA damage and consequential cell death due to exposure to ionizing radiation may not be 
the only significant factor determining the effect of RT [29]. Better understanding the complex 
mechanisms behind the microvascular response to radiation may enable a better understanding of 
overall tumor response to treatment, allowing for improved treatment planning.  
Immediate changes in tissue perfusion as a result of cancer treatments have been closely 
studied and documented previously. In the context of RT, many studies have observed changes 
in vascular function in both clinical and pre-clinical studies. Park et al reported in an extensive 
review that lower dose treatments (<10 Gy) induced mild vascular damage, while larger doses 
(>15 Gy) resulted in significant vascular damage that was reflected in both vessel density and 
perfusion [30]. Long term vascular changes in higher-dose scenarios have been largely 
consistent. In another study, it was reported that 10 Gy radiation induced an increase in perfusion 
immediately after radiation, and then a significant decrease in perfusion 26 hours post treatment. 
Perfusion returned to normal levels 7-11 days after treatment [31]. Others have reported similar 
trends in blood perfusion: a sudden hyper-perfusion, followed by a sudden hypo-perfusion, and 
then gradual return to normal perfusion levels.  
The correlation of these relatively short-term response trends to long-term outcome is an 
interesting question. Several studies have suggested that initial tumor vascular response may be a 
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predictor of long-term treatment response. It was reported by that immediate vascular volume 
and perfusion changes following high dose (>10 Gy) RT precede long term outcomes. 
Specifically, a marked increase in perfusion and neovascularization was a potential predictor of 
long-term tumor regrowth [32–34]. This was corroborated by Song et al, who also reported 
increased revascularization in tumors that regrew 15 days after 30 Gy treatment [30]. 
Interestingly, Maeda et al demonstrated early microvascular changes (within just 2 days) in 
response to a single dose of radiation in a mouse optical window chamber model suggesting that 
the tumor microvasculature is a highly dynamic and responsive system [35].  
In addition to functional changes in tissue microvasculature, previous studies have 
reported changes in vessel structure in response to RT. Specifically, Bullitt et al demonstrated the 
use of vessel segmentation and tortuosity calculations from magnetic resonance angiography 
(MRA) images of the brain and correlated radiation treatment outcome with vascular 
normalization [36]. It was observed that increased tortuosity was associated with tumor 
recurrence, suggesting that the analysis of vessel shape may be an important biomarker for 
assessing treatment response.   
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CHAPTER 2: 
Overview of Cancer Imaging 
 
2.1 Modalities for Cancer Imaging 
Cancer can be diagnosed using a variety of techniques including blood tests, physical 
examination, tissue biopsy, genetic tests, and imaging. Technology is rapidly improving in all of 
the diagnostic areas whether it is the development of antibodies that are more specific to blood 
serum antigens or advancements in Next Generation Sequencing/High-throughput Sequencing 
for personalized cancer screening [37–39]. Radiology plays an important role in the 
multidisciplinary approach to cancer diagnosis and disease management; it has dominated the 
area of cancer diagnostics for over half a century due to its non-invasiveness, standardized 
techniques, and versatility in application. Imaging is applied in a number of ways in oncology, 
including routine screening, biopsy guidance, and treatment monitoring to name a few. Nearly 
every imaging modality is currently used in cancer diagnosis (ultrasound, computed tomography 
(CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single photon 
emission computed tomography (SPECT), bone scans, Optical Coherence Tomography (OCT), 
each with its unique strengths and weaknesses [40–42].  
Anatomical imaging is best used for identifying solid masses in the body and is most 
commonly used in the clinic. Imaging modalities commonly used for anatomical imaging include 
ultrasound, MRI, and CT. Often a combination of these imaging modalities will be used 
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depending on the type and location of the tumor. Traditional grayscale ultrasound imaging is 
useful for imaging soft tissue tumors with high sensitivity which may otherwise be difficult to 
see with x-ray imaging. It is a real-time imaging modality, inexpensive, and globally accessible. 
CT and MRI excel at allowing physicians to perform 3D full body imaging of the body to 
visualize location, morphology, and size of lesions [43].  
Functional imaging adds an additional dimension to cancer diagnosis by offering 
information regarding the molecular activity of the cancer. Two examples include PET and 
SPECT imaging, which can be used to identify regions of abnormal molecular activity (e.g. 
localized increase in radiolabeled glucose uptake is indicative of cancer). While PET and SPECT 
have high sensitivity and specificity to the radiolabeled compounds that are used for imaging, 
they lack resolution and anatomic detail. Development of multimodal imaging techniques, such 
as PET-CT or PET-MRI have made it possible to visualize anatomical and functional 
information simultaneously [43]. The fusion of anatomical and functional imaging has been the 
backbone of image aided cancer diagnostics, and the same theories can be applied to assessing 
cancer response to therapy as well. 
 
2.2 Imaging for Assessing Response to Therapy 
The long standing standard for assessing treatment response is quantifying changes in the 
size of the tumor mass. Since tumor measurements can be easily performed serially and 
noninvasively with traditional imaging modalities, imaging is typically the preferred method for 
assessing response to treatment. Traditionally, uni-dimensional or bi-dimensional measurements 
taken in the axial plane are used to represent tumor size; however, more recent studies have 
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demonstrated that volumetric measurements may provide a more accurate assessment. The 
Response Evaluation Criteria in Solid Tumors (RECIST) was published in 2000 as a guide of 
international standards for assessing tumor response to therapy using medical imaging, 
specifically CT and MRI. It is commonly used by physicians on a daily basis as part of their 
treatment monitoring (which also includes symptom surveillance and other tests). RECIST 
categorizes lesions as measurable and non-measurable. Measurable lesions are >20 mm on chest 
x-ray (or >10 mm on spiral CT) [27]. Measurable lesions are further categorized as complete 
response, partial response, stable disease, or progressive disease based on percent increase or 
decrease of the sum of the largest diameters. Non-measurable, or non-target lesions are also 
categorized as complete responders, stable disease, or progressive disease based on their 
disappearance or persistence, or the appearance of new lesions.  
The advancement of new cancer drugs and targeted treatment strategies has warranted the 
development of a new method of assessing tumor response. At the time RECIST was published, 
many of the chemotherapeutics used were cytotoxic drugs which functioned by directly killing 
cancer cells. Therefore, a change in the number of cancer cells was represented by a change in 
the TV. New treatment strategies, such as anti-angiogenic drugs, or drugs that inhibit cancer cell 
proliferation by interrupting relevant cell signaling pathways, do not directly kill the cancer cells 
yet have still demonstrated sufficient tumor control and disease management [44]. Considering 
the effects of these new types of treatments requires a different biomarker that looks beyond the 
size of the tumor. 
Nuclear medicine (PET and SPECT) and contrast imaging techniques for MRI, CT, and 
ultrasound have proven useful in assessing molecular changes and changes in physiological 
function. For example, FDG (Fluorodeoxyglucose) PET is the most commonly used radionuclide 
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for PET imaging to assess glycolytic metabolism of the tumor [45]. PET is often coupled with an 
anatomical imaging modality such as PET-CT or PET-MRI which registers the molecular 
(functional) information with the anatomy.  
Dynamic contrast-enhanced CT and MRI enable quantification of contrast perfusion in 
the tissue of interest [46]. Depending on the type of therapy, blood perfusion in the tumor may be 
expected to increase or decrease. For example, a decrease in tumor perfusion might be expected 
after the delivery of an anti-angiogenic drug. Changes in tumor metabolism and blood perfusion 
are two of many alternative biomarkers that can be used for assessing response to therapy that 
may paint a more accurate picture of treatment effects than TV. 
As discussed previously, angiogenesis plays a crucial role in tumor development and the 
resulting tumor vasculature has distinctive characteristics such as increased tortuosity, density, 
and permeability. Angiogenesis can be quickly triggered in response to physiological stimuli 
such as inflammation and hypoxia [47]. Since these changes have been shown to occur much 
sooner than the physical growth of the tumor mass itself, the ability to assess microvascular 
changes related to a particular disease would potentially increase the sensitivity of diagnostics 
and improve disease management.  
 
2.3 Medical Ultrasound Imaging 
Apart from x-ray imaging, ultrasound imaging is the oldest, most fundamental imaging 
modality used in medicine. There are many advantages of using ultrasound over other imaging 
techniques, such as MRI and CT. Ultrasound is a non-ionizing imaging technique and when used 
within clinical parameters, produces no adverse bio-effects. It is highly portable with a footprint 
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of less than 1 m3, and requires just a small consult room. Recent advancements in ultrasound 
instrumentation have condensed the size of an ultrasound scanner to the size of a table or phone--
in fact, there are now ultrasound apps that are available for the iPhone. This is in contrast to CT, 
MRI, and nuclear imaging, which require significantly more expensive equipment and dedicated 
facilities to house the scanners. These large imaging rooms are usually equipped with a 
procedure room and an external control room so that interference from ionizing radiation or 
magnetic fields do not affect bystanders or other unprotected equipment. Ultrasound is also 
significantly inexpensive. Standard diagnostic ultrasound and chest x-ray cost $150-300, while 
MRI, CT, and nuclear imaging can cost anywhere from $500-$2,500 depending on the 
application (prices based on no insurance coverage) [48].  
Medical ultrasound is most commonly used for anatomical imaging. Unlike the full-body 
imaging capabilities of CT and MRI, ultrasound has an extremely limited field of view of ~2-7 
cm laterally, and 15-20 cm axially. However, ultrasound offers higher resolution, anywhere from 
100-1000 µm depending on the desired frequency and application. In terms of cancer imaging, 
traditional brightness mode ultrasound (b-mode or gray-scale ultrasound) can detect abnormal 
lesions with high sensitivity, however it has low specificity in lesion subtyping or assessing 
malignancy [49].  It is also difficult to visualize blood with conventional ultrasound, and 
standard Doppler techniques are limited and unable to detect smaller vessels due to limited 
scattering of blood components and a low impedance mismatch between blood and the 
surrounding tissue.  
To improve the imaging specificity to tissue vasculature, a contrast agent is typically 
used. For example, iodinated or gadolinium based contrast agent is intravenously injected for 
contrast CT or MRI imaging, respectively. Similarly a microbubble contrast agent can be used 
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for contrast enhanced ultrasound imaging (CEUS) which provides sufficient contrast between 
blood and the surrounding tissue.  
 
2.4  Ultrasound Contrast Imaging 
Microbubble contrast agents are composed of an inert, high molecular weight gas core 
stabilized by a phospholipid or albumin shell. Other molecules may be incorporated with bubble 
shell. For example, polyethylene glycol (PEG) is often incorporated into lipid shell 
microbubbles, which acts as a stealth agent, reducing its visibility to the reticuloendothelial 
system. The bubbles are on the order of 1-3 µm in diameter, roughly the size of red blood cells 
[50]. This means that once introduced into the vascular supply, they remain strictly an 
intravascular contrast agent. This is in contrast to gadolinium and iodine based contrast agents 
for CT and MRI, which eventually diffuse out of the vasculature. As a pure intravascular agent, 
the microbubbles increase the specificity of microvessel detection using ultrasound. The half-life 
of the bubbles is on the order of 3-5 minutes, depending on the organism that is being imaged; 
for humans, it is approximately 3 minutes. The shell components are cleared by the body through 
the liver and spleen, while the core gas is transferred out through the lungs and simply breathed 
out.  
Microbubbles possess very interesting properties which enable high contrast-to-tissue 
vascular imaging. Since the core of the bubble is gaseous, the acoustic impedance mismatch 
between the tissue/blood and microbubbles is very high, resulting in increased ultrasound 
scattering [51]. Further, the gas core expands and contracts as it is interrogated by an ultrasound 
pulse, resulting in a non-linear, harmonic oscillations, in contrast with highly linear tissue 
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reflections centered at the fundamental frequency with weak higher harmonic signal. Various 
ultrasound algorithms take advantage of the non-linear oscillations for contrast imaging. For 
example, pulse inversion is a technique where two consecutive pulses (the second pulse is 
inverted) are transmitted such that their echoes are summed, subtracting the odd harmonics and 
summing the resultant even harmonics [52]. This effectively removes the linear fundamental 
frequency, while retaining the non-linear, harmonic (primarily 2nd order) signals.  
CEUS has been used heavily in echocardiography, and in the last decade, techniques such 
as perfusion imaging and molecular imaging have been tested in preclinical and clinical settings 
in a variety of organ systems and cancer types [50]. While the applications of CEUS are 
seemingly ubiquitous, the resolution of typical CEUS imaging schemes are limited and 
differentiation of individual vessels cannot be achieved. The ability to resolve small vessels 
allows for further quantification of the vascular environment within a tissue, such as vascular 
density and morphology. With traditional CEUS imaging, it is difficult to discern increases in 
contrast intensity as a function of increased microvasculature or local increase in perfusion. 
Higher ultrasound frequencies (>15 MHz) are required for higher resolution imaging, however 
the microbubble contrast agents resonate most effective when excited at low frequencies 
(microbubble resonance is approximately 1-5 MHz) [53]. Interestingly, the response of 
microbubbles when excited at low frequencies is significantly broadband relative to the 
surrounding tissue, and can produce energies that can be detected at high frequencies greater 
than 30 MHz [54,55]. The ability to excite microbubbles at their resonance frequency and 
receive super-harmonic content would enable significantly higher resolution CEUS. 
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CHAPTER 3: 
Overview of High-Resolution CEUS 
 
3.1 Acoustic Angiography 
Acoustic Angiography (AA) is CEUS imaging technique developed by the Dayton Lab at 
the University of North Carolina at Chapel Hill that implements the concept of superharmonic 
imaging, which utilize the broadband microbubble response for high-resolution microvascular 
imaging [56].  
 
Figure 3. 1. Acoustic Angiography and B-mode images. A) B-mode image in the coronal view of 
a tumor located in the right flank of a rat indicated with yellow arrows. B) A coronal maximum 
intensity projection of 3D intensity data from a stack of 2D AA images in the same imaging area. 
Using AA we can visualize the tumor tissue and microvasculature with exceptional tissue 
rejection. 
 
In this method, a low frequency transmit pulse at a moderate pressure (0.6-1.0 MPa) is 
delivered around the resonance frequency of the microbubble. The resulting broadband 
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microbubble response spans as high as the 8-10th order harmonics. The lower harmonics (mostly 
containing tissue signal) are filtered out using a high-pass filter. Since such broadband 
transducers do not exist that can perform both a low frequency transmit and a high frequency 
receive, a prototype confocal dual-frequency transducer was developed containing a low 
frequency (1-4 MHz, close to microbubble resonance) outer ring element for transmission and a 
high-frequency (25-30 MHz) inner element for receiving (Figure 3.2). The large bandwidth 
separation of the transmit and receive frequencies enables the detection of broadband 
microbubble signals while rejecting linear tissue signal. AA is significantly more sensitive to 
microbubble contrast agents resulting in a high contrast to tissue ratio (CTR) of up to 20 dB, and 
because such a high receiving frequency is used, the resolution is approximately 100-200 µm, 
higher than conventional contrast imaging techniques [54].  
 
Figure 3. 2. The RMV prototype dual-frequency probe used for AA imaging. The low-frequency 
annulus is used for transmission, and the high-frequency inner element is used for receiving. The 
transducer “wobbles” laterally to produce a curvilinear type ultrasound image.  
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3.2 Vascular Metrics Derived from Acoustic Angiography 
A stack of 2D images acquired by translating the ultrasound probe in the elevational 
dimension can be constructed into a 3D visualization of tissue microvasculature. There are 
several vascular metrics that can be derived from AA 3D data. Using the grayscale 8-bit raw 
intensity data, thresholding algorithms can be used to filter out weak microbubble contrast signal 
from slow-flowing unresolvable vessels, below the resolution limit of AA and binarize the 
remaining resolvable vessels (>100 µm) -- this is performed over the entire 3D volume. For 
instance, volumetric vascular density (VVD) can be measured with the binarized image by 
summing the number of pixels above the grayscale threshold and dividing by the number of 
pixels within the user defined region of interest (ROI) encompassing the tumor region [57].  
Individual resolvable vessels can also be segmented using specialized segmentation 
software, which generates an array of 3D vectors representing the tubular centerline for each 
vessel enabling quantitative morphological assessment. As discussed previously in section 2.1, 
tumor vessels are often characterized as highly tortuous. Using AA and segmentation methods, 
we calculate vessel tortuosity using three metrics: distance metric (DM), sum of angles metric 
(SOAM), and total curvature metric (TCM) [58]. The DM is calculated by dividing the length of 
the extracted vessel path by the length of the end-to-end vessel secant. The SOAM is calculated 
by integrating the angular changes throughout the centerline of the vessel, divided by the length 
of the extracted vessel path. TCM is calculated by summing the total curvature of the vessel and 
dividing by total path length [58]. All three metrics are complementary to describing vessel 
tortuosity—for example, SOAM and TCM are more sensitive to tightly coiled vessels.  
Tumor necrosis (or severely hypovascular regions) can also be detected and quantified. 
As discussed previously, tumor necrosis has been shown to correlate with angiogenesis and poor 
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prognosis. By reducing the frame-rate of imaging, we can increase our sensitivity to microbubble 
signal, including signals from smaller, slow flowing vessels (Figure 3.3). This results in an image 
similar to conventional CEUS, however the increased resolution and contrast sensitivity allows 
us to draw precisely defined lines of regions of necrosis and calculate percent necrosis (PN). 
Using a slower frame-rate image, we apply the same binarization algorithm used for VVD 
calculations and count the pixels below the grayscale threshold. 
 
Figure 3. 3. The effect of frame averaging on AA images. The AA image on the left was 
acquired without frame averaging. Contrast signal from microvessels below the resolution limit 
can be detected. In this way, areas of no perfusion (considered severely hypoxic or necrotic) are 
easily discernable and can be extracted and measured using basic image processing. The image 
on the right is after 2 frame averaging. The signal intensity is significantly lowered since signal 
from small, slower flowing vessels is averaged out between frames. The result is that individual 
vessels can be visualized during 3D reconstruction. 
 
3.3 Prior Studies with Acoustic Angiography 
Previous work has largely focused on demonstrating AAs ability to quantify statistical 
differences in vascular tortuosity and density between normal and cancerous tissue. Gessner et al 
published results using segmented vessel tortuosity analysis from 438 vessels that demonstrated 
an increase in both DM (23.76% higher) and SOAM (50.73% higher)  in rat fibrosarcoma (FSA) 
tumors compared to normal tissue [59]. Shelton et al later demonstrated that AA alone could 
19 
 
detect statistical increases in DM and SOAM in tumors as small as 2-3 mm [60]. This established 
the detection of “pre-palpable” tumors using quantification of microvascular features alone.  
The work discussed in this dissertation builds upon this previous work and extends the 
application of AA to assessing tumor microvascular response to treatment, specifically RT. We 
investigate the quantification of various vessel features and evaluate their sensitivity to 
microvascular changes with the intent of developing a predictive measure of successful or 
unsuccessful response to treatment. 
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CHAPTER 4: 
AA for Assessing Tumor Microvascular Response to RT1 
 
4.1 Overview 
Previously we have demonstrated the ability to discriminate healthy from cancerous 
tissue solely by quantifying abnormal microvasculature using AA. As tumors develop, their 
microenvironment become denser with tortuous and leaky vessels. Additionally, quickly growing 
tumors become hypoxic resulting in regions of severe hypovascularity and necrosis. We 
hypothesize that changes detected in the tumor microvascular microenvironment using AA in 
response to RT are correlated with long term survival. In this study, we longitudinally performed 
AA imaging on tumor bearing rats treated with a single dose of RT, measured five tumor 
vascular features at each time point, and determined the correlation with long term survival 
compared with TV measurements. 
 
 
  
                                                 
1 This chapter previously appeared as an article in the Journal of Theranostics. The original citation is as follows: 
Kasoji SK, Rivera JN, Gessner RC, Chang SX, Dayton PA. Early Assessment of Tumor Response to Radiation 
Therapy using High-Resolution Quantitative Microvascular Ultrasound Imaging. Theranostics. 2018;8(1):156-168. 
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4.2 Materials and Methods 
4.2.i Rat and Tumor Models 
All animal surgical and imaging procedures were reviewed and approved by the 
University of North Carolina at Chapel Hill Animal Care and Use Committee prior to conducting 
this study. Rat FSA tumor tissue was subcutaneously implanted in the right flank of 30 female 
Fisher 344 rats as previously described [61]. Rat FSA was originally induced and isolated from 
Fisher 344 rats injected with the carcinogen, methylcholantrene [62]. Rat FSA is characterized as 
a local, non-metastasizing tumor that is highly vascular and oxygen dependent [62,63]. Because 
of its high vascularity, it is an appropriate tumor model for AA imaging after RT, since we are 
specifically interested in the tumor vascular response to therapy. Because rat FSA is oxygen 
dependent, avascular regions typically undergo tissue necrosis [63].  
 
4.2.ii RT and Monitoring 
Once the tumors reached their target treatment size of 5-10 mm in diameter in the longest 
dimension of the sagittal plane, the tumors were given a single dose of radiation. The rats were 
split into four different dose cohorts and received either 0 Gy (treatment control, n=9), 15 Gy 
(n=8), 20 Gy (n=5), or 25 Gy (n=8) of radiation. The dose levels were determined during a 
longitudinal pilot RT study (unpublished) that was conducted at 0, 5, and 20 Gy. We found that 5 
Gy had no tumor control, and 20 Gy had roughly 50% complete response (tumor shrinkage and 
eventual disappearance) and 50% partial response (initial tumor shrinkage followed by a delayed 
tumor regrowth). We selected a dose level of 15-25 Gy as it allowed us to investigate the dose 
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dependent correlation between TV change and microvascular change for both complete response 
and partial response groups with similar statistics. 
The rats were anesthetized using vaporized isoflurane and oriented in the left lateral 
recumbent position on a heating pad throughout the duration of the treatment with front and rear 
paws stabilized on the heating pad with medical tape. Positioning was performed using a 
rotatable rat positioning table (VisualSonics, Toronto Canada) so that the tumor was completely 
irradiated while minimizing exposure to the abdominal region (Figure 4.1). The rats were treated 
with a Primus II clinical linear accelerator (Siemens Healthcare, Malvern, PA) with a dose 
prescription of 6 MV photons, 2 cm x 2 cm collimated radiation field size at 100 cm source-to-
skin-distance (SSD), and 1 cm of water-equivalent build-up material.  All rats were monitored 
daily for the first 2 weeks following treatment, and then every third day thereafter.  Additionally, 
the animals were all fed identical diets consisting of regular protein pellets and both calorie-rich 
and hydrating gels to mitigate excessive weight-loss and water-loss due to dehydration in the 
case of intestinal distress caused by radiation enteritis. 
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Figure 4. 1. Setup used for irradiation and ultrasound imaging. A) (Front view) For irradiation, 
the rat was positioned on a heating pad mounted to a 3-axis rotatable base. The heating pad was 
rotated to an angle such that irradiation beam was centered on the tumor while minimizing 
exposure to the abdominopelvic region. The 1 cm water-equivalent bolus was then placed on top 
of the tumor region. B) (Top view) The rat was secured to the heating pad using medical tape. A 
2 cm x 2 cm irradiation field size was used. C) (Front view) For imaging, the rat was positioned 
on the same heating pad, oriented parallel to the floor such that the tumor was facing up. A 
custom designed water bath was used to separate the transducer from the gel while still being 
continuously coupled to the tumor, so that the mechanical translation of the transducer would not 
displace the gel causing decoupling and introducing air bubbles. D) (Side view) The transducer 
was mechanically translated in the elevational dimension for 2 cm for each scan.  
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4.2.iii Imaging Procedure 
Rats were imaged immediately prior to radiation for baseline measurements. After the 
radiation treatment, imaging was performed daily for 3 consecutive days and then every 3 days 
for approximately 30 days or until the tumors reached the maximum size of 2 cm in the longest 
diameter.   
During each imaging session the rats were anesthetized using vaporized isoflurane and 
positioned on a heating pad as described above. A tail vein IV catheter was inserted for constant 
microbubble contrast infusion during AA imaging. Microbubble contrast agents were prepared 
in-house using sterile techniques, as previously described [61]. The contrast was diluted with 
0.9% sterile saline in a 1:1 ratio. The contrast agent was administered as a small bolus of 50 µL 
immediately followed by a constant rate of infusion of 40 µL/min using a pre-clinical infusion 
pump. Contrast was infused for 30 seconds before imaging was initiated to allow contrast flow to 
achieve a steady state and then was continued for the duration of the imaging scan. A total 
contrast volume of approximately 180 µL was injected for one AA scan. The tumor region of the 
rat was shaved and depilated and ultrasound gel was applied onto the tumor region for ultrasound 
coupling. A custom imaging bath was used for all imaging to minimize gel decoupling during 
mechanical translation of the transducer (Figure 4.1). All imaging was performed on a Vevo 770 
pre-clinical ultrasound scanner (VisualSonics, Toronto, ON, Canada) with a custom prototype 
dual-frequency transducer modified from a VisualSonics RMV707 probe, as previously 
described [64]. This transducer utilized a 4 MHz transmitter and a 30 MHz receiver, and was 
mechanically swept to acquire 2D images, and then translated in the elevational axis to acquire 
3D data.  A b-mode (anatomical) image volume was acquired over a 2 cm region, followed an 
AA scan over the same region. The elevational step size for each image was 100 µm. Two-frame 
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averaging with a frame rate of 3 frames/second was used for all AA imaging to improve the 
signal-to-noise ratio for producing optimal images. 
 
4.2.iv Image Analysis 
The b-mode images were used to calculate TV. The caliper feature on the Vevo 770 
imaging software was used to measure the longest tumor diameter in each image axis to 
approximate the ellipsoidal volume of the tumor. The AA images were post-processed using 
MATLAB (MathWorks, Natick, MA), TubeX, and VesselView to measure VVD, PN, and vessel 
tortuosity through the SOAM, DM, and the TCM [65,66].  
It is important to identify and remove large hypoechoic regions to not overestimate the 
total perfused tissue volume [67,68]. We assumed that large hypoechoic regions were due to 
necrosis and hypoxia, based on tumor ex vivo observations and prior literature that describes rat 
FSA as a highly oxygen dependent tumor [63]. These hypoechoic regions will be referred to as 
“necrotic” for simplicity, which encompasses necrotic and perinecrotic regions. For identifying 
necrotic regions, a de-noising 2D median filter was applied to each frame of the AA image slices 
to smooth the image and then a threshold was used to create a volumetric binary mask which 
identified large dark regions. The ratio of the number voxels representing necrotic regions within 
the ROI and the number of voxels representing the entire tumor ROI was calculated as PN.  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑁𝑒𝑐𝑟𝑜𝑠𝑖𝑠 (𝑃𝑁) =  
# 𝑣𝑜𝑥𝑒𝑙𝑠 𝑜𝑓 𝑖𝑑𝑒𝑛𝑡𝑖𝑓𝑖𝑒𝑑 𝑛𝑒𝑐𝑟𝑜𝑠𝑖𝑠
# 𝑜𝑓 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑡𝑢𝑚𝑜𝑟 𝑅𝑂𝐼
 
The previous volumetric binary mask used for identifying PN was then reapplied to the 
original AA image followed by subsequent thresholding to identify the vessels using the local 
26 
 
Otsu threshold method [69]. VVD was calculated by dividing the number of voxels representing 
vessels by the number of voxels representing the tumor tissue sans necrosis (Figure 4.2). 
 
Figure 4. 2. Summary of the image analysis for calculating VVD. A single 2D slice of a 3D 
volume is shown in this figure. A) The original AA ROI. B) The original image, de-noised with a 
2D median filter. C) The binary vessel image of the original ROI produced by applying an Otsu 
threshold. D) The hypoechoic mask made by applying a threshold on the de-noised image (B). E) 
The mask (D) applied to the binary vessel image (C). Arrows indicate resolvable vessels that 
have been converted into binary by thresholding. 
 
For vessel tortuosity analysis, individual vessels were segmented using a custom 
segmentation software (Tubex) designed by Bullitt and Aylward et al which uses a ridge 
traversal method to extract tubular objects from 3D images [66]. Using the b-mode images, 
volumetric ellipsoidal ROIs were drawn encompassing the tumor and the surrounding tissue 
(each major axes was 1.5 times the radius of the measured tumor diameter). Only the tumor 
region and surrounding tissue was included in the segmentation analysis since including normal 
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vessels far from the tumor region reduces the sensitivity of detecting changes in tortuosity.  The 
raw image ROI data was preconditioned into isotropic voxels prior to segmentation. The 
automatic, single vessel segmentation algorithm requires a manual definition of a seed point 
(performed by clicking a potential vessel in either the coronal or axial slice mode), which then 
automatically extracts the rest of the vessel by following the image intensity ridge representing 
the centerline of the calculated tubular structure (Figure 4.3). The algorithm performs a spatial 
up-sampling function which smooths the trajectory of each vessel. The radii of the vessel is also 
determined at each centerline point [66]. Initially for each image, approximately 100-200 vessels 
were segmented but were later filtered based on segment length to remove vessels that were too 
short to perform tortuosity metrics. A threshold vessel length of 500 points was used for all 
tortuosity analyses. The segmented data was imported into a second analysis software 
(VesselView) also developed by Bullitt and Aylward, which calculated SOAM, DM, and TCM 
(among other metrics) for each vessel.  
 
Figure 4. 3. An example of vessels segmented from an AA image. The yellow circle represents 
the location of the tumor, which is visible in the right AA image. The vessels inside the tumor 
are noticeably more bendy and irregular compared with the vessels far outside of the ROI. 
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4.2.v Data Analysis 
At the end of the study, treated rats were retrospectively categorized based on the 
treatment outcome as either partial response (initial treatment response followed by tumor 
recurrence) or complete response (full treatment response resulting in complete tumor 
disappearance). The 20 Gy study was terminated early at day 20 due to imaging schedule 
constraints. All complete responders were monitored for the duration of the study (30 days) for 
tumor regrowth, followed by an additional 30 days.  
TV and all microvascular metric (MVm) (VVD, PN, SOAM, DM, TCM) growth curves 
for all individual rats were normalized by their respective baseline (pre-treatment) values. Initial 
TV growth curves (before tumor regression) and tumor recurrence rates were characterized by 
calculating their doubling times (Dt) using the equation: 
Dt = (T – T0) × (log(2)/log(Vf)) – log(V0) (Dt – doubling time; T0 – time of initial 
measurement; T – time of initial measurement; V0 – initial volume; Vf – final volume)  
Similarly, TV regression was characterized by calculating the tumor halving times (Ht) 
using the equation: 
Ht = (T – T0) × (log(1/2)/log(Vf)) – log(V0) [70] (Ht – halving time; T0 – time of initial 
measurement; T – time of initial measurement; V0 – initial volume; Vf – final volume) 
Different phases of the MVm (initial response, regression, and recurrence phases) were 
characterized using linear regression.  
TVx represents the beginning of the recurrence phase identified using TV measurements 
for an individual tumor. Corresponding time points were labeled for each of the microvascular 
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metrics as well (labeled collectively as MVmx). Statistical differences in growth curves and TVx 
and MVmx values were evaluated using the Mann-Whitney U-test, and differences observed 
between dose groups were evaluated with the Kruskal-Wallis test, followed by the Tukey Post-
Hoc multiple comparison test (α = 0.05). All statistical analysis was performed in MATLAB. 
 
4.3 Results 
4.3.i TV and VVD Results 
The treatment response statistics and sample sizes for each dose group are summarized in 
Table 1. Partial responders, complete responders, and untreated tumors in each dose group 
present distinctly different VVD and TV growth curves (Figure 4.4).  
Table 4. 1 Treatment Response Statistics by Dose Group 
 15 Gy 20 Gy 25 Gy 
Partial Response 5 (63%) 3 (60%) 3 (38%) 
Complete Response 3 (38%) 2 (40%) 5 (63%) 
Total Treated Tumors: 8 5 8 
Table 4. 1. Summary statistics of the treatment outcomes for each dose group. Partial response 
refers to tumors that initially responded but regrew and progressed, and complete response refers 
to tumors that completely disappeared after treatment. 
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Figure 4. 4. A comparison of tumor volume (A, C, E) and tumor microvascular density (B, D, F) 
growth curves for complete responders (solid black), partial responders (dotted black), and 
untreated tumors (solid gray) for each dose group. Sample sizes for complete and partial 
responders, and untreated groups were 3, 4, and 2 for the 15 Gy group, 2, 3, and 5 for the 20 Gy 
group, and 5, 3, and 2 for the 25 Gy cohorts, respectively. Error bars represent standard 
deviation. Partial responders undergo a transient decrease in vascular density that correlates with 
tumor regression and eventually increases, correlating with tumor recurrence. For complete 
responders, both TV and VVD decrease. The large error bars in TV and VVD curves are 
expected due variability in tumor growth as well as heterogeneity of vascular supply. 
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Initial Response 
Untreated tumors underwent normal, uninterrupted exponential volume growth with a 
mean doubling time of 1.9 ± 0.5 days (median: 1.9 days; range: 1.4 days; IQR: 0.6 days). All 
treated tumors presented delayed TV growth after the treatment (day 0) until day 3, at a growth 
rate significantly less (p=0.009) than compared to the untreated tumors with a mean tumor 
doubling time of 3.8 ± 2.6 days (median: 3.2 days; range: 11.7 days; IQR: 2.0 days). There was a 
non-significant decrease in the average tumor doubling time for treated tumors as RT dose 
increased. VVD of all treated tumors increased by an average of 18 ± 13%, significantly greater 
(p=0.023) than in untreated tumors, which increased by 4 ± 6%. There were no significant VVD 
or TV differences between partial and complete responders within each dose group (Table 2). 
Tumor Regression 
By day 5, all treated tumors experienced tumor regression where both TV and VVD 
decreased. There was no statistical difference in the regression rates of either TV or VVD 
between complete and partial responders in the 15, 20, and 25 Gy treatment groups. For 
complete responders, the tumors continued to shrink and completely disappeared between days 
15 and 20, accompanied with decreasing VVD (Table 2).  
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Table 4. 2 Tumor Volume and Volumetric Vascular Density Growth Curve Statistics 
 Untreated All 
Treated 
15 Gy 20 Gy 25 Gy 
   Complete 
Response 
Partial 
Response 
Complete 
Response 
Partial 
Response 
Complete 
Response 
Partial 
Response 
Tumor Volume Doubling 
time – Initial Response 
(days) 
1.9 ± 0.5 3.8 ± 2.6 
 
(p=0.009) 
5.6 ± 3.4 3.4 ± 0.5 2.4 ± 1.4 
5.5 ± 1.2 5.7 ± 4.7 3.6 ± 0.7 3.3 ± 0.3 2.3 ± 1.3 2.4 ± 1.9 
Volumetric Vascular Density 
increase – Initial Response  
(%) 
4.3 ± 6.1 18.1 ± 
12.7 
 
(p=0.023) 
21.0 ± 15.8 26.5 ± 10.2 10.0 ± 5.1 
22.3 ± 
21.3 
20.5 ± 
14.0 
23.8 ± 
15.3 
28.3 ± 
8.9 
8.6 ± 5.9 12.4 ± 
2.9 
Tumor Volume Halving time 
– Regression 
(days) 
~ 3.0 ± 1.0 3.2 ± 0.7 2.8 ± 0.3 2.9 ± 1.4 
2.5 ± 0.3 3.8 ± 0.5 3.0 ± 0.6 2.7 ± 0.1 2.1 ± 0.3 1.3 ± 1.6 
Volumetric Vascular Density 
Regression (%) 
~ -12.8 ± 
9.3 
-10.9 ± 4.9 -20.9 ± 14.7 -9.3 ± 5.0 
-10.4 ± 
6.1 
-11.7 ± 
3.5 
-26.0 ± 
19.6 
-17.5 ± 
14.1 
-11.1 ± 
5.7 
-6.2 ± 1.0 
Tumor Volume Doubling 
time – Recurrence 
(days) 
~ 4.7 ± 2.1 3.6 ± 0.8 6.4 ± 3.4 4.5 ± 1.2 
Volumetric Vascular Density 
Recurrence (%) 
~ 5.2 ± 3.2 7.2 ± 3.6 4.7 ± 3.3 3.2 ± 1.4 
Table 4. 2. Statistical analysis of tumor volume and volumetric vascular density growth curves for each dose group. Significant 
differences were observed in TV doubling time and VDD increase, immediately post-treatment. Treated tumors experienced delayed 
tumor growth (increased TV doubling time) immediately after treatment while VVD in treated tumors increased at a significantly 
higher rate than untreated tumors. There were no other statistically significant growth curve trends between treated and untreated, and 
complete and partial responders. 
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Tumor Recurrence 
All partial responders rebounded and recurred between days 10 and 20 as indicated by 
their TV growth curves. VVD began to increase between days 7 and 11 and was also associated 
with tumor recurrence. Tumor recurrence occurred (non-significantly) earlier as dose increased 
as indicated by decreasing average TVx; VVD recurrence (average VVDx) was not statistically 
different between dose groups. When comparing TV and VVD curves for each individual tumor, 
the increase in VVD was observed earlier than the increase in TV (Figure 4.5). Figure 4.6 
visually illustrates TV and VVD changes where VVD begins to increase while TV is still in the 
regression phase (Figure 4.6). 
 
Figure 4. 5. Example of vascular density (left) and tumor volume (right) growth curves from a 15 
Gy partial responder. All measurements were normalized to baseline values. In this particular 
partial responder failure, vascular density begins to increase as early as day 8, while tumor 
volume regrowth occurs later. The increase in the growth curve for both metrics demarcates the 
recurrence phase for partial responders, which is illustrated by the shaded region. The tumor 
volume and vascular density growth curves of partial responders in each dose group behaved 
similarly. 
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Figure 4. 6 A visual comparison of vascular density and tumor volume changes during the tumor 
regrowth phase of the same 15 Gy partial responder plotted in Figure 4. Vascular density (right) 
noticeably increases from day 7 to day 19, while tumor volume (left) size continues to decrease 
until day 19. The tumor boundary in the b-mode images is indicated by the solid yellow line. 
Note that microvascular data is shown as a maximum intensity projection but is actually a 3-D 
data set. 
 
Increase in VVD for individual rats was observed 10.25 ± 1.5 days, 6 ± 0 days, and 4 ± 
1.4 days earlier than increases in TV, in the 15 Gy*, 20 Gy*, and 25 Gy cohorts, respectively 
(Figure 4.7, *p<0.05). The initial TVs were 157.8 ± 5.9 mm3, 182.9 ± 68.1 mm3, 201.4 ± 77.4 
mm3, for the 15, 20, and 25 G groups, respectively. Variation in initial TVs between groups was 
due to tumor growth difficulties; specifically at the time of treatment, tumors either did not 
develop or grew too large (> 1 cm in diameter) to be continued in the study.  There were non-
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statistically significant differences in TV and VVD measurements between complete responders 
and partial responders; specifically, partial responders exhibited higher TVs and VVDs (Table 
3).  
Table 4.3 Average Initial TV and VVD Values 
Dose 
(Gy) 
Average Initial TV (mm3) 
(*p<0.05) 
Average Initial VVD 
(*p<0.05) 
 Partial 
Response 
Complete 
Response 
Partial 
Response 
Complete 
Response 
15 171 ± 52 108 ± 40 0.25 ± .04 0.16 ± 0.10 
20 230 ± 67 137 ± 110 0.26 ± 0.01 0.20 ± 0.05 
25 290 ± 77 169 ± 39* 0.27 ± 0.02 0.25 ± 0.04 
Table 4. 3. Average initial tumor volume and initial vascular density values for each dose group. 
Larger initial tumor volumes were associated with partial response. While not statistically 
significant, the average initial vascular density for partial responders was greater than complete 
tumor response. This becomes less pronounced as dose increased. 
 
Figure 4. 7 Dose dependence of the early detection of treatment failure by tumor vascular 
density. Partial responder identification using vascular density (black) occurred earlier than using 
tumor volume (gray). With increasing dose, the difference in the time of identification between 
vascular density and tumor volume decreased. ([*] significant at p < 0.05). 
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No severe adverse health effects or significant weight loss were observed in any of the 
rats during the entirety of the study. The orientation of the rat during treatment minimized 
irradiation of the abdominopelvic region, resulting in less toxicity than in our previous studies 
where the rat was oriented perpendicular to the radiation beam. Mild radiation enteritis was 
experienced by less than 5 rats which resulted in loose stool and an average of 5 grams or 3% 
loss of body weight. This was mitigated with supplementary high calorie food and hydrogel 
water (Methods section). All rats with recurring tumors were euthanized at the end of the study. 
Rats with successfully treated tumors have been kept indefinitely (>180 days) since the end of 
the study and have not shown any signs of tumor recurrence. 
 
4.3.ii  PN, SOAM, DM, and TCM Results 
No significant differences in PN, SOAM, DM, and TCM growth curves were measured 
between partial responders, complete responders, and untreated controls at any time points. 
There were no dose dependent differences observed in any of the treatment groups. A summary 
of the growth curves is presented in Supplementary Figure C.1. There is an average increase in 
PN measured in the partial responders in all dose groups, however the average trends in PN for 
complete responders is inconsistent. Tortuosity measurements were compared at time points 
where VVD and TV clearly showed differences between partial and control responders, however 
no significant differences were found between groups. These data are summarized in 
Supplementary Figure C.2.  
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4.4 Discussion and Conclusions 
We have previously demonstrated that AA can visualize microvasculature with high-
resolution and various quantitative metrics are sensitive to certain abnormal microvascular 
structural properties (e.g. tortuosity, density) that allow us to discern cancerous tissue from 
normal tissue [59,60].  Based on previous research that has demonstrated that microvascular 
remodeling occurs within days after radiation exposure using optical imaging, we hypothesized 
that quantification of microvascular changes using AA may indicate response to therapy sooner 
than using TV alone, the current clinical standard for assessing response to treatment [35]. In this 
work we have demonstrated that quantitative AA is sensitive to changes certain microvascular 
features induced by RT and its feasibility as a tool for predicting treatment response.  
We believe the clinical implications of our data are significant. In this tumor model, we 
have demonstrated that by quantifying the dynamic microvascular response to RT, tumor 
recurrence can be detected earlier than using TV measurements alone. In clinical practice, 
irradiated tumors often do not significantly change in size until 3-4 months after treatment and 
therefore post-treatment imaging is also not performed during this time [71]. For any cancer 
patient, early detection of cancer and early assessment of treatment response is critical for 
maximizing the chances for improving or maintaining quality of life. By decreasing the wait time 
between treatment and post-treatment evaluation, we may be able to increase the probability of 
successfully modifying an unsuccessful treatment strategy to one that is tailored to the patient. 
This is specifically important for RT, which by itself is often used with radical intent more than 
in a palliative setting.  
The results in this study using a rat FSA model demonstrate that changes in VVD is a 
biomarker that presents differently in complete and partial responders in response to RT, and that 
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VVD regrowth associated with tumor recurrence in partial responders occurs significantly sooner 
than TV regrowth. In the tumors that present complete response, VVD and TV both decrease at 
similar rates until the tumor completely disappears.  
We observe three phases after RT in both the VVD and TV curves, as described by Kozin 
et al: 1) initial treatment response presented by a continued increase in TV and VVD, 2) tumor 
regression phase presented by decrease in TV and VVD, and in partial responders, 3) tumor 
recurrence phase [72]. In the initial treatment response phase we observed an increase in VVD 
that occurred at a significantly greater rate than in untreated tumors, most likely due to short term 
inflammation and subsequent hypervascularization caused by the high-dose RT. This observation 
is supported by previous pre-clinical studies that observed hyperperfusion immediately after RT 
[30].  Days before TV recurrence (TVx) is measurable in the partial responders, the tumors begin 
to undergo a rapid increase in VVD which can be visualized on imaging and quantitatively 
measured. While we do not have data supporting why VVD increases earlier than TV, prior 
evidence suggests that the tumor endothelium experiences stress induced expression of vascular 
endothelial growth factor (VEGF) and αvβ3-integrins, therefore evading cell death and possibly 
promoting revascularization and tumor cell proliferation [73,74].  
In this study, we observed that the average TV in the partial responders was larger than 
the complete responders, in all dose groups, although the size difference was not significant due 
to variance. The increased likelihood of failure in RT treatment of larger tumors is consistent 
with radiation biology theory [75,76]. As expected, the TV threshold corresponding with 
complete response increased as a function of radiation dose (Table 3). We also observed that 
average initial VVD was greater in partial responders compared to complete responders; 
however, the differences were not significant and require further investigation (Figure 4.7). 
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Although a higher VVD at the time of treatment might be associated with an increase in tumor 
oxygenation and improved RT outcome, this hypothesis remains unanswered with conflicting 
reported results from previous studies [77].  Hypoxic tumors are known to be more radioresistant 
than normoxic tumors due to a number of reasons including the lower probability of reactive 
oxygen species produced by ionizing radiation forming fewer DNA strand breaks as well as the 
negative effect of hypoxia on the pathway for DNA damage repair resulting in a more 
radioresistant cell type [78]. While many previous studies have observed a positive correlation 
between VVD and therapeutic response, others have reported that VVD has no effect, or an 
inverse correlation with treatment response [77,79]. We speculate that in this particular tumor 
model, endothelial cells within the larger tumors, which inherently have a higher VVD, may 
undergo a smaller fraction of lethal radiation damage than smaller tumors and can eventually 
repair, possibly encouraging tumor regrowth. Due to the variability in tumor growth rates and 
unforeseen treatment scheduling complications, our initial size distribution was not comparable 
in all dose groups and is a confounding factor in explaining the effect of initial VVD on 
treatment outcome.  
We observed earlier tumor recurrence with increasing dose; however, this requires further 
investigation. There are two possible explanations. First, as mentioned previously, the average 
initial (pre-treatment) TV was larger as dose increased, which may have resulted in a lower 
tumor cell kill fraction despite being treated with higher doses. Second, there is evidence that 
suggests that hypoxia induced by higher dose RT activates the unfolded protein response, 
protecting against hypoxia and resulting in the ability to more aggressively proliferate and 
metastasize [80]. However, further investigation is required to determine if FSA is affected by 
hypoxia induced stress.  
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We chose to use a simple, single high-dose fraction treatment to demonstrate feasibility 
of our imaging technique. Our dosage scheme was determined based on pilot study results 
(unpublished) of a longitudinal RT study performed at 0, 5, and 20 Gy in the same rat and tumor 
model. In the 20 Gy treatment group, approximately ~50% resulted in complete response. We 
chose doses between 15 and 25 Gy to investigate the TV and VVD differences between complete 
responders and partial responders while also determining any dose dependent responses. 
Conventional dose fractionation, or the division of the total radiation dose into multiple smaller 
doses over 7-8 weeks, is clinically used to reduce healthy tissue toxicity by allowing cellular 
repair in between successive treatments [81]. At this point, the effect of a dose fractionated 
scenario on tumor VVD is unclear and is an important, clinically relevant question that still 
needs to be answered. Our high-dose treatment conditions are more relevant to stereotactic body 
radiotherapy (SBRT) or stereotactic radiosurgery (SRS), and hypo-fractionated RT, which 
precisely deliver high dose radiation to the target tissue with just a single or few treatments [82]. 
Hypofractionation and SBRT/SRS, while relatively new and controversial in the field of RT, are 
promising techniques that may reduce toxicity while improving tumor control [82–84]. The 
results from this initial study motivate us to conduct further investigation under experimental 
conditions closer to more clinically relevant applications that incorporate conventional and hypo-
fractionated RT.  
The microvascular changes observed in this study are specific to the Fisher 344 rat FSA 
tumor model. Since this tumor strain has been shown to be highly oxygen dependent we made an 
assumption that areas of hypovascularity (hypoechoic regions) represented necrotic and 
perinecrotic regions [63]. The motivation for removing the hypoechoic regions was to prevent 
overestimation of the perfused tissue volume. However, histology was not performed to confirm 
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the hypoechoic regions as necrotic/perinecrotic to validate our analysis. This can be performed in 
future studies using the TUNEL assay and haemotoxylin and eosin staining [85].   
As mentioned previously, tumor hypoxia and necrosis play an important role in tumor 
response to radiation [17,80]. However, no significant correlation between tumor necrosis and 
regrowth was observed. The reason for this may be two fold. First, tumor recurrence may not 
necessarily separate partial from control responders based on malignancy. Rather the data 
suggest that initial tumor size likely plays a role in treatment failure. While recurring tumors may 
develop necrotic regions, complete responding tumors are rapidly dying and exhibit loss in 
vascularity. Since PN is a fraction of the TV, any necrotic region measured in smaller, regressing 
tumors may account for a large percentage of the total volume.   
Based on the previous studies by Bullitt et al, that demonstrated vascular normalization in 
response to successful RT response, a similar response trend was expected in our study. 
Interestingly, no significant changes in vascular morphology was detected using any of the 
metrics. The reason for this discrepancy is uncertain, but we suspect that the treatment conditions 
may have an effect on the microvascular response. The cancer treatment described by Bullitt et al 
was whole brain radiation [36]. Although treatment details were not shared, whole brain 
radiation is typically fractionated by 20-40 Gy/5-10 fractions, limiting a single fraction to 3-4 Gy 
[86]. This is in contrast to the treatment conditions used in this study which consisted of a single 
high dose of radiation in the range of 15-25 Gy, in a small rodent model. Revisiting vessel 
tortuosity changes is warranted with future studies with gentler treatment conditions (i.e. 
fractionated radiation, 15 Gy/5 doses).  
In addition to the treatment conditions, the response may very well be tumor model 
dependent. The diversity of human tumors encompasses with a wide range of neovascularization 
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patterns, including both avascular (hypoxic) and vascular development [87]. Further 
investigation using this technique in different types of human-derived tumor models is warranted 
since the microvascular response after exposure to radiation will likely vary among different 
tumor types. Regardless, we are encouraged from these results that quantitative microvascular 
measurements using AA may significantly improve the current methods for treatment 
assessment.  
In our study we retrospectively categorized the treated tumors as complete response or 
failure based on the final treatment outcome. The development of a predictive tool indicating 
treatment outcome based on repeated VVD (or other vessel morphological features) and TV 
measurements will be highly relevant to the clinical translation of this diagnostic technique.  
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CHAPTER 5: 
Preliminary Functional Principal Components Analysis on Longitudinal Microvascular 
Imaging Data Sets 
 
5.1 Overview 
In the previous chapter, we demonstrated the feasibility of using AA to quantify changes 
tumor microvascular structure in response to a single dose of broad-beam RT. We investigated 
five metrics describing VVD, PN, and vessel tortuosity. We observed significant differences 
between partial and complete responders using the VVD metric only – PN, SOAM, DM, and, 
TCM did not yield any significant differences in any of the groups (within response groups and 
treatment cohorts). An increase in VVD preceded TV regrowth in partially responding tumors 
post- RT. This result suggests that we may be able to assess non-responsive tumors sooner using 
microvascular imaging, then compared to TV alone. In this chapter, we will explore functional 
data analysis (FDA) techniques to demonstrate the predictive potential of tumor microvascular 
imaging. The FDA model will be based on VVD data and will first be developed on a training 
set of rat tumor data, and later evaluated using a test data set. We hypothesize that by using FDA 
techniques on longitudinal data we may be able to discriminate partial responders from complete 
responders with significant sensitivity and specificity compared to TV. Our objective here is to 
demonstrate a proof-of-concept, clinically relevant tool for early assessment using quantitative 
microvascular imaging.  
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5.2 Functional Data Analysis on Biologically Relevant Longitudinal Data 
FDA is a branch of statistics that characterizes data from repeated measures for a single 
test subject or condition [88]. The defining characteristic of functional data includes specifically 
curves and trajectories. Normal multivariate regression techniques are commonly performed on 
time series data, within discrete time points, however this ignores the time-varying behavior that 
actually describes the shape of a particular curve or trajectory [89]. The basic principle of FDA is 
that instead of expressing individual observations at a given time point as scalar values or 
vectors, they are represented as functions. For instances, in a very simplified context, a single 
observation can be described as a derivative function instead of a scalar value. The result of 
analyzing time series data in a functional manner is that the generated models are continuous and 
smooth, with reduced noise from the observed data [90].  FDA has been most commonly applied 
in econometrics, but can be applied to biologically relevant longitudinal data (specifically in the 
fields of bioinformatics and biostatistics). The difference between conventional “functional data” 
and “longitudinal data” is that the latter is typically described as sparse and irregular. FDA can 
be used to predict smooth trajectories even when the number of longitudinal data points is 
limited within each subject. One method of FDA for longitudinal data is functional Principal 
Component Analysis (fPCA). Traditional PCA is a versatile method of dimensional reduction for 
extracting linearly uncorrelated variables from a set of data potentially containing correlated 
variables. This can be applied efficiently to longitudinal data to reduce a high dimension of 
trajectories (for example from a large longitudinal data set containing multiple test subjects) into 
a lesser number of dimensions. Muller and Yoa et al describe in detail the techniques and 
applications for fPCA as well as other FDA methods [90–92].  
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Here we demonstrate the implementation of fPCA on longitudinal data derived from AA 
microvascular images for predicting the response of individual subject repeated measurements 
based on the trajectory analysis of many training subjects.  
 
5.3 Methods 
5.3.i Acquisition of Additional Data 
In order to increase our sample size, we treated 14 additional rats with 15 (n = 9) and 20 
(n = 5) Gy doses of broad beam RT. Tumor models, imaging acquisition and analysis, and RT 
were consistent with what was previously described in Chapter 4. Since longitudinal 
measurements of PN, SOAM, DM, and TCM did not yield significant differences between 
partial and complete responders, only VVD and TV metrics were used for fPCA.  
 
5.3.ii Data and Statistical Analysis 
The rats imaged in the second round of experimentation were categorized as partial or 
complete responders based on their final response outcome at the end of the study, same as 
previously described. After image processing and microvascular feature quantification, we ended 
with approximately 256 longitudinal time points from 35 rats treated with either 15, 20, or 25 Gy 
of radiation. Untreated, control rats were not used for data analysis.  
For the prediction model, fPCA was used for longitudinal data analysis for sparse and 
irregular data sets. fPCA was performed on a training set, which consisted of 60% of all the 
longitudinal data from the treated rats (the percentage was applied to both partial responders and 
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complete responders, indiscriminant of the treatment conditions). Typically ratios such as 80/20 
or 70/30 are used, but due to the relatively small sample size, a 60/40 split was preferred, which 
would allow us to perform statistics on the testing set (the remaining 40% of the data). The 
principal components (PCs) fitted values from the training set were then applied to the testing 
set. fPCA scores from two eigenvectors were used for performing binomial logistic regression 
with a logit link to estimate coefficients β1 and β2. Then, a linear predictor, in the form of: 
𝜂 =  𝛼 +  𝛽ଵ𝜉ଵ +  𝛽ଶ𝜉ଶ 
was used for binary classification of partial (1) and complete responders (0), where 𝜂 is the 
predicted value from the logistic regression, α, β1 and β2 are estimated coefficients from the 
logistic regression, and ξ1 and ξ2 are the eigenvectors from the fPCA. For TV and VVD, one and 
two eigenvectors (PCs) are used, respectively. The number of PCs required for the model was 
determined by achieving a threshold of 90% variance explained by the sum of the first n number 
of PCs [93]. The fPCA and functional longitudinal analysis techniques have been adopted from 
Müller et al [90]. Receive operator characteristic (ROC) curves were then constructed for 
presenting true and false positive rates. The validation using the test set was performed at 
varying time point durations in order to assess the change in sensitivity and specificity of the 
prediction over time. The shortest assessment duration was from day 0 to day 7, and ranged to 
day 0 to day 30. Twenty-three sets of ROC curves were constructed for both TV and VVD and a 
plot of the area-under-the-curve (AUC) was created for each metric against the time point at 
which the peak AUC was achieved (representing the highest true positive rate and the lowest 
false positive rate). 
fPCA was performed for both VVD and TV separately. P-values and estimated errors, as 
well as the F-statistic and p-value of the overall regression were calculated for each assessment 
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duration and for each metric at the assessment duration iterations 1 (days 0-8), 6 (days 0-13), and 
23 (days 0-30). The fPCA testing was repeated with the exclusion of days 1-5 in all data sets. 
These days were excluded to remove the effect of initial tumor size as well as the complex initial 
delayed growth response immediately after irradiation in both TV and VVD growth curves.  
 
Figure 5. 1. The 23 iterations of fPCA testing included systematically varied assessment 
durations ranging from day 0 to days 5-30. These iterations were repeated with days 0-5 
excluded from analysis.  
 
All fPCA analysis was performed using the Principal Analysis by Conditional 
Expectation (PACE) package for MATLAB [90,92,94]. Logistic regression and ROC curve 
generation were performed separately, also using MATLAB. 
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Figure 5. 2. Example results from the binomial logistic regression and fit to a logit curve from 
day 14. Better lateral separation is evident between the two groups with VVD (left) compared to 
TV (right). 
 
5.4 Results  
The scree plot for TV calculated that the first two PCs account for 97.035% of the 
variance in the data and for VVD, the first three PCs account for 95.634% of the variance in the 
data. The number of PCs describes how many orthogonal modes of variation are required to best 
explain the data. 
 
 
Figure 5. 2. Scree plots for TV and VVD. The cut-off for Variance explained was set at 95%. 2 
PC was chosen for TV and 3 were chosen for VVD in order to satisfy the cut-off condition.  
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Figure 5.3 illustrates the change in AUC over the assessment duration iterations for both 
TV and VVD.  
 
 
The peak AUC for TV was calculated to be 0.95 (maximum specificity and sensitivity of 
100% and 89%, respectively) at day 18, and the peak AUC for VVD was calculated to be 0.98 
(maximum specificity and sensitivity of 100% and 89% respectively) at day 14. VVD has a 
higher AUC value of 0.98 at day 14 compared to TV, which has a value of 0.89. From day 18 to 
30, AUC for both TV (mean AUC = 0.98 ± 0.02) and VVD (mean AUC = 1 ± 0.0) are 
comparable and above 95%.  
 
 
 
 
 
Figure 5. 3. Plots of AUC of ROC curves over the different testing iterations.  
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5.5 Discussion and Conclusions 
Previously, retrospective analysis of longitudinal AA data showed significant differences 
in VVD as a function of time between partial and complete responders occurred earlier than 
using TV. The objective in this study was to develop a proof-of-concept predictive tool using 
existing statistical methods for assessing tumor response to RT for an individual test subject with 
limited longitudinal data points. We have demonstrated the application of fPCA on AA data for 
analyzing group trajectories of treated tumors for discriminating partial from control responders 
and then applying them in an untested set of longitudinal data for treatment response 
classification. Using exploratory longitudinal analysis in Chapter 5, we were able to identify key 
features differentiating partial and control responders and untreated tumors. Key features 
included initial TV and VVD, and regression and recurrence growth rates. We also observed a 
dose dependent response that affected the time at which recurrence occurred. The high 
dimensionality of the trajectory data (growth rates, initial values, inflection points and local 
minima and maxima, etc) is difficult to analyze using normal linear regression models. fPCA 
helped to reduce the number of trajectory dimensions into 2 dimensions for TV and 3 dimensions 
for VVD (given by the number of PCs used for each metric).  
An FDA type approach for longitudinal AA data is very beneficial as it focuses on the 
trajectories rather than the absolute values of the measurements. The large error bars calculated 
within groups is expected due to varying initial tumor sizes and overall intrinsic variability in 
individual tumor behavior. By using only the mean response trajectory of the entire group, 
response classification is inefficient and prone to large errors because of these variabilities. 
Normalization remedies this effect only slightly, as it is still dependent on the initial absolute 
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measurement. The result using mean trajectory analysis or linear regression is that at any given 
time-point, the correlation between the metric and response is low.  
The results from the fPCA analysis suggests that VVD can classify partial from complete 
responders earlier than TV, although the specificity and sensitivity for both metrics are 
comparable. The difference between the two metrics is much more pronounced with days 0-5 
included in the analysis. Specifically, the shape of the curves between days 0-5 has a significant 
effect on the predicted trajectories. The reason for the drastic decrease in TV performance while 
VVD performance slightly improved is still unclear, but may likely be a function for the variance 
explained cut-off and the low sample size of this study.  
 Sparsity and irregularity in longitudinal data sets may first seem to be an insufficiency 
for statistical analysis, but this strongly depends on the type of data being acquired. In our case, 
measurement error manifested in the form of noise in our growth curves. TV measurement 
growth curves are straightforward and well understood. This is in contrast to VVD which is a 
noisy metric, and measuring with too high of a frequency (in terms of number of days between 
imaging time points) will add unnecessary low-level noise. This is evident in our earlier imaging 
experiments where imaging was performed on 5-7 consecutive days post- RT. Sparse 
measurements reduces this noise. The opposite extreme is also not beneficial, however this can 
be counteracted by increasing the sample size and irregularity of the time points.  
Other techniques for removing noise that were trialed but not used or discussed in this 
chapter included binning of time points that were too close together, reducing measurement 
noise, and smoothing of data points that were far apart using cubic spline interpolation. Both 
techniques were used coincidentally for performing multivariate linear regression on the 
derivatives of the growth curves, however this was abandoned due high error and over estimation 
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of the slopes. Curve smoothing using splines and derivative analysis should be revisited in future 
studies, considering appropriate samples sizes and conditions, as it is related to fPCA techniques 
and has also been shown to be a suitable method for longitudinal data analysis [95]. 
There are several limitations to the structure of the analysis that should be accounted for. 
With each test iteration, the number of points added to the test were decreased since complete 
responders had no data once the tumor was immeasurable (typically around day 25). Adding 
more data points did strengthen the result, however this only affected the partial responders’ 
scores. Additionally, we used a small sample size relative to previous studies that demonstrate 
the use of fPCA. Many FDA type studies incorporate measurements that are automatically 
recorded by instrumentation resulting in hundreds of data points, or are performed 
retrospectively on large data sets [96]. The sample size (n=35 treated test subjects) was further 
decreased since the data set was split into training and testing sets. Accumulating more data is 
necessary for performing robust fPCA. Also, in the study in Chapter 5, we observed a significant 
dose dependent response, specifically in TV growth rates. In fPCA analysis, we grouped all dose 
groups together (excluding untreated tumors). Owing to the small sample size, it was not feasible 
to split training and testing sets within dose groups. Treatment dose was added as a secondary 
predictor for logistic regression, however it did not add any value in improving the response 
classification. In the future, a cross-validation method can be used for testing with small data 
sets. 
Finally, only one vascular metric (VVD) was used. Other microvascular metrics 
discussed in the previous chapters were not included since no significant differences between 
groups were measured at any time point. As discussed previously, additional investigation is 
required to better understand the behavior of vessel tortuosity and tumor necrosis in response to 
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RT, and should not be necessarily excluded from future studies. Specifically, the effect of the 
radiation treatment conditions on vessel tortuosity should be revisited since prior work has 
demonstrated clinical relevance of vessel tortuosity on assessing RT outcome. Adding additional 
predictors (including variables such as treatment dose, and weight as a marker for treatment 
toxicity) to the model improves the fit of the prediction model, assuming an appropriate increase 
in sample size and observations. 
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CHAPTER 6: 
Extensions, Limitations, and Future Directions 
 
6.1 Molecular Imaging for Assessing Response to Radiation Therapy 
6.1.i Overview 
Ultrasound molecular imaging (USMI) is a branch of CEUS that employs microbubbles 
that are specially designed to bind to biomarkers expressed on the endothelium for targeted 
imaging [50,61,97]. Certain angiogenic specific biomarkers (i.e. VEGF, αvβ3) are highly 
expressed in tumor situated endothelium, and since angiogenesis is a key characteristic of tumor 
growth, these biomarkers are ideal candidates for targeted imaging of cancer. There is already a 
considerable amount of literature demonstrating the use of USMI for detecting cancers and 
assessing response to therapy (Figure 6.1) [98–101]. To our knowledge, no one has reported a 
longitudinal study using USMI for early assessment of tumor response to RT.  
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Figure 6. 1. USMI of a murine angiosarcoma model, using SFRP-2 targeted microbubbles. 
USMI was demonstrated as a non-invasive method for monitoring angiosarcoma response to 
therapy. Figure reprinted with permission from [101] (Copyright © 2014 Tsuruta et al).   
 
In our previous results, we observed increases in VVD prior to TV regrowth in partially 
responding tumors. The growth of new vessels implies that the tumor conditions are favorable 
for angiogenesis. We hypothesize that even prior to measurable increases in VVD using AA, 
USMI may be able to detect early expression of angiogenic biomarkers (Figure 6.2).  
 
Figure 6. 2. The black features represent the standard treatment and imaging schedule, and the 
red feature represents the hypothesized period of angiogenic signaling. Since expression of 
VEGF stimulates angiogenesis, it is theorized that USMI can detect tumor regrowth even sooner 
than VVD. 
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6.1.ii Methods 
A pilot study was conducted consisting of 10 tumor bearing rats, 8 of which were treated 
with a single 15 Gy dose of RT. Animal preparation, tumor models, imaging schedules, and 
radiation procedures were consistent as what was described in Chapter 4.  
A very similar longitudinal imaging study was performed using USMI instead of AA on a 
Siemens Acuson Sequoia 512 scanner with a 15L8 linear array transducer. All imaging was 
performed using Cadence Pulse Sequencing (CPS) mode, a CEUS technique employing both 
pulse inversion and amplitude modulation [102]. Targeted microbubble contrast agents were 
prepared with biotinylated sc-VEGF and were designed to target to VEGFR-2 [103]. Briefly, the 
methods for USMI are as follows. The size distribution and concentration of the prepared 
targeted microbubble contrast agents were measured prior to imaging at each time point using a 
particle sizing system (AccuSizer, Particle Sizing Systems, Port Richey, FL). An appropriate 
volume of microbubbles were pipetted into 100 uL of sterile saline so that the final microbubble 
count was approximately 4x107 bubbles (this number of bubbles was determined by previous 
calibration tests). Prior to contrast injection, the ultrasound probe was positioned over the tumor 
using the same imaging apparatus described in Figure 4.1, and a 3D b-mode scan was acquired 
followed by a baseline scan in CPS mode.  
The contrast agent was then injected intravenously as a bolus via the tail vein. The initial 
contrast wash-in was captured as a cine clip in the midplane, and once the tissue was fully 
perfused, a 3D scan of the entire tumor was acquired. Microbubbles were allowed to circulate up 
to 7 minutes before a second 3D scan was acquired to capture the bound targeted bubbles. The 7 
minute wait time allowed for microbubble binding to the targeted sites and clearance of unbound 
bubbles. After the second 3D scan was acquired, a series of high MI pulses were delivered to 
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clear all bound bubbles, followed by an additional minute of wait time to allow for reperfusion of 
any remaining microbubbles in circulation. A third 3D scan was then finally acquired to capture 
any free flowing bubbles that may be considered as background noise (Figure 6.3). 
 
Figure 6. 3. Sample 2D images from 3D scans from a single tumor. A) a b-mode image used for 
measuring the tumor volume, B) a baseline image for quantifying tissue background noise, C) 
the fully perfused tumor used for detecting potential regions of necrosis, D) the targeted contrast 
image after 7 minutes, and E) the post microbubble destruction image for detecting residual free 
flowing bubbles. 
 
The first 3D scan which captured the fully perfused tumor was used to detect any necrotic 
regions of the tumor. These regions were subsequently subtracted from the molecular targeted 
scans to prevent underestimation of molecular targeting. The average intensity of the post-
destruction scan was subtracted from the intensity of the targeted scan, and a single intensity 
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value as recorded for each animal and at each time point. TVs were also measured by estimating 
the ellipsoidal volume based on three orthogonal diameters of the tumor.  
 
6.1.iii Results and Discussion 
Tumors were classified as partial responders and complete responders at the end of the 
study. Of the eight treated tumors, 6 displayed complete response while 2 displayed a partial 
treatment response. As expected, there was a greater average initial TV in the partial responders 
compared to the complete responders, however this difference was not significant. All treated 
tumors underwent similar response phases as described in Chapter 4.  Interestingly, the measured 
USMI signal trends was similar for all treated tumors and was characterized by an initial 
decrease in signal intensity and then from day 8, molecular targeted signal begins to increase 
(Figure 6.4). In complete responders, this increase in molecular targeted signal occurs despite 
decreasing TV. In depth analysis of this data set was not performed because there were several 
limitations and confounding variables that were overlooked.  
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Figure 6. 4. Summary of average longitudinal curves of TV (left) and USMI (right). USMI 
suggests there may be some underlying differences between partial and complete responders, 
however the results are not statistically significant. The dip in the USMI signal for the control 
group around day 7 is an example of the potential ACB effect on microbubble targeting. 
  
First, the accelerated blood clearance (ABC) of PEGylated particles significantly affects 
the clearance of microbubble contrast agents in longitudinal studies [104]. Specifically, the 
production of PEG-specific antibodies in response to the PEG found on the microbubble shell, 
promotes faster clearance, and the rate of clearance has been recently shown to increase with 
successive microbubble doses. One of the potential solutions to the ABC effect is to pre-dose the 
rats with PEGylated lipid solution to “prime” the antibody production before the start of the 
study. In this way, the measurements are more consistent throughout the duration of the actual 
study.  
In this study, we captured only one time point after the bolus injection. An alternative 
method is to capture a time-intensity curve (TIC) of the bolus injection and calculate the area 
under the curve for each TIC as a measure of molecular targeted signal [103]. This also ensures 
that any lasting ABC effect after pre-dosing is accounted for. Other variables that need to be 
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carefully considered in future experiments is the accuracy of the microbubble concentration and 
selecting a dose that is sufficient for maximum microbubble binding, yet low enough for to allow 
for efficient clearance of unbound bubbles. The disadvantage of using a high microbubble dose 
is that the wait time for unbound bubble clearance is too long, risking the shearing or dissolving 
of already bound bubbles which eventually results in lower targeted signals. The microbubble 
dose of 4x107 bubbles was based on previous work. However, due to the ABC effect, the 
clearance was too fast. The optimum concentration will need to be reassessed before the next 
iteration of the study. 
While in this study we used the Sequoia 512 for contrast imaging, USMI and AA can be 
performed simultaneously using the same RMV transducer. Shelton and Lindsey et al previously 
demonstrated molecular imaging with high contrast sensitivity and SNR, by implementing AA 
imaging with targeted microbubbles [105]. While the results from our pilot study were 
inconclusive and the usefulness of USMI for assessing tumor response to RT is still uncertain, 
the possibility of performing both high-resolution microvascular imaging and USMI using the 
same system allows us to correlate functional and anatomical imaging of microvasculature 
simultaneously.  
 
6.2 Current Limitations of Acoustic Angiography and Improvements 
The current dual-frequency prototype transducer used in the studies described in Chapter 
4 and other preclinical studies suffers from resolution and imaging depth limitations. The 
resolution of AA is between 100-200 µm, which places a limitation on the smallest size tumor 
that can be accurately quantified in terms of microvascular features. For example tumors less 
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than 1 mm in diameter may inaccurately measure VVD as high as 20-50% due to the resolution 
limitation. Despite this limitation, it is a significant improvement to conventional contrast 
imaging techniques.  
Additionally, due to the fixed focus of the dual-frequency transducer, our depth of field 
was limited to approximately 1.0 cm axially with a maximum depth of penetration of ~2 cm. 
Tumors near 2 cm in diameter were clipped at the top and bottom in order to maintain the focus 
of the transducer in the center of the tumor. Decreasing the transducer receiving frequency will 
improve the imaging penetration depth and depth of field, however the signal-to-noise ratio is 
compromised due to the reduced separation between tissue signal and higher harmonic contrast 
signal. Conversely, increasing the receiving frequency will improve resolution, but at the cost of 
decreasing contrast sensitivity, penetration depth, and depth of field. It is worth noting that new 
super-resolution imaging techniques may provide an alternative solution to imaging angiogenic 
vasculature with an order of magnitude better resolution once the technology matures. However, 
super resolution imaging still requires tens of minutes to acquire a 3D volume of data due to data 
acquisition and processing limitations [106]. Despite these limitations, AA has remarkably high 
resolution and contrast sensitivity relative to clinically available CEUS techniques. Further, 
development of a linear array dual-frequency transducer will enhance AA with increased depth 
of field and faster image acquisition required for clinical translation [107,108].  
 
6.3 CEUS and Radiomics  
There has been a recent surge of interest in developing models for predicting a patient’s 
outcome to cancer therapy. The field of Radiomics, for example, has been established to use 
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large sets of minable MR, CT and PET imaging data to extract quantitative features such as 
tumor sphericity, homogeneity, and volume. When combined with other patient medical data, it 
can be analyzed using advanced bioinformatics statistical techniques to determine correlations to 
tumor behavior and treatment response [109]. Similarly, with AA image data, we can extract 
additional quantitative features that describe microvascular characteristics of certain tumors and 
their response to therapy. We plan to continue investigating changes in vessel morphology and 
molecular expression in response to RT in future studies.  Contrast-enhanced ultrasound imaging 
is a safe, inexpensive, and highly accessible imaging modality with many applications in all 
fields of oncology, and with on-going technical improvements, AA is a promising and clinically 
translatable imaging technology. 
While the biological basis for the variation of tumor response to radiation is still not 
entirely understood, there is a growing body of evidence that suggests that the tumor 
microvascular environment plays a significant role in radiation treatment efficacy. Our objective 
in these studies was to assess tumor response to radiation by quantifying changes in vascularity 
that may be associated with treatment outcome. Our results demonstrated that vascular changes, 
specifically increases in VVD, are a potential biomarker for assessing long-term tumor response 
to RT. We believe that providing a more timely and reliable method for assessing treatment 
response may enable clinical treatment decisions to be made earlier than the current standard of 
care, therefore improving cancer patient outcomes. 
 
 
 
 63 
  
 
 
CHAPTER 7: 
In-vitro and In-vivo Testing of a Prototype Dual-Frequency Array Transducer 
 
7.1 Overview 
7.1.i Development of a Dual-Frequency Linear Array for Acoustic Angiography 
AA uses a low frequency transmit and high frequency receive at significantly separated 
bandwidths. An ultra-broadband transducer centered at a single frequency capable of efficiently 
transmitting at low frequencies near microbubble resonance and receiving high frequencies (8-
10th harmonic difference), currently does not commercially exist. Capacitive micromachined 
ultrasonic transducers (CMUTs) may potentially be able to accomplish this, however the 
technology is still in its infancy. As a solution, a dual-frequency probe was developed, with two 
separate and co-aligned elements mechanically translated in the lateral dimension. As a 
prototype transducer, this “wobbler” type probe has been sufficient for many significant 
preclinical studies to demonstrate feasibility of AA for microvascular imaging, as demonstrated 
in Chapter 4. The current transcutaneous prototype dual-frequency transducer for AA is limited 
to imaging from outside the body at a single focal depth (limited to ~1.5 cm), due to the confocal 
single element design. Additionally, due to the single element design, more advanced imaging 
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schemes such as angular compounding, multi-focal imaging, and dynamic receive beam forming 
cannot be performed. 
Current clinically available transducers are either linear, curvilinear, or phased array 
transducers containing up to hundreds of individually excitable elements, which allows for more 
advanced beamforming and imaging techniques. The major advantages of using linear array 
transducers over a single element wobbler type transducer include the ability for electronic 
focusing, improved lateral resolution and sensitivity, parallel scan lines which form a uniform 
image in depth, as well as increased frame-rate and depth of field. Also clinically speaking, 
linear arrays are more ergonomic as they are easy to couple against the human body and can be 
easily designed into form factors for various imaging applications. The current challenge in 
adapting linear array imaging to AA is the requirement for a dual-frequency transmit and 
receive. Starting in 2002, Bouakaz et al and Van Neer et al reported the design of an interleaved 
dual-frequency phased-array for superharmonic imaging which consisted of alternating elements 
with center frequencies of 2.8 MHz and 900 kHz (Figure 7.1) [110–113]. While this transducer 
design was a significant step towards clinical superharmonic imaging, due to the interleaved 
element scheme, the kerf for the high-frequency elements would include the width of the low 
frequency elements as well, reducing receive sensitivity and increasing sidelobes (resulting in 
image blurring). Over the years there have been many other reports of dual-frequency 
transducers for imaging and imaging/therapy applications [114].  
Recently Kim et al and Li et al developed a novel proof-of-concept dual-frequency, co-
linear array with a stacked design approach of low-frequency (2-3 MHz) transmit and high-
frequency (10-20 MHz) receive (Figure 7.1). This design overcomes the kerf limitations of the 
interleaved design hence reducing the sidelobes. While the lower receive frequencies compared 
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to the RMV probes (4/30 MHz) enables greater depth of penetration and may be suitable for 
transcutaneous imaging, the frequency range is ideal for intracavitary (i.e. transvaginal, 
transrectal) applications, specifically for prostate imaging [108,114].  
 
7.1.ii Dual-frequency Transrectal Ultrasound for Prostate Cancer Imaging 
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. 
The American Cancer Society estimates over 220,000 new cases and 28,000 deaths (12% death 
rate) in the United States alone in 2015 [115]. Currents methods of diagnosis and clinical staging 
have been shown to have low sensitivity and specificity, limiting early detection and 
intervention. Early diagnostic blood work for abnormal levels of prostate specific antigen (PSA) 
is clinically recommended for men over the age of 50, followed by digital rectal examination 
(DRE). Since increases in PSA levels and enlargement of the prostate are not specific to PCa, 
both preventative measures have poor specificity and suspicious masses felt during physical 
examination often require follow up biopsies. Moreover, DRE is only sensitive to tumors that are 
in the peripheral and lateral regions of the prostate. Prostate tumor biopsies, which typically 
consist of 10-12 cores (Sextant biopsy scheme), have false-negative rates of 20-30%.  Increasing 
the number of biopsy samples improves the diagnostic sensitivity, but suffers a trade-off with 
increasing patient discomfort and risk of infection and hemorrhage [116–119].  
 For PCa detection and prostate tumor biopsy guidance, traditional gray scale ultrasound 
cannot adequately identify diseased tissue if it is isoechoic with the surrounding healthy 
parenchyma. Unfortunately, up to 32% of all prostate tumors are isoechoic. The classical 
presentation of solid tumors on ultrasound is hypoechoic with the surrounding tissue; however 
only 17-57% of biopsy cores extracted from hypoechoic masses are diagnosed as PCa. To date, 
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the use of traditional b-mode ultrasound is limited to biopsy guidance of the needle to the 
different anatomical locations of the prostate [120]. MRI and MRI-TRUS fusion guided biopsies 
have increased the accuracy of needle core biopsies, but require substantially more expensive 
equipment and the use of two different imaging modalities [121]. 
 Contrast enhanced transrectal ultrasound (CE-TRUS) has been tried as a method for 
targeting areas with higher perfusion within the prostate for extracting biopsy cores. However, 
results have shown that while CEUS targeted biopsy significantly improves the detection of high 
grade/high volume PCa, its accuracy of identifying malignant lesions is confounded by the 
enhancement of benign tissue [122]. Additionally, CE-TRUS lacks the contrast resolution to 
resolve individual vessels for measuring vessel morphology and density within the tumor, which 
may be a more sensitive measure of malignancy [123]. Currently using imaging alone, CT, MRI, 
and gray scale TRUS are not sensitive to small tumors (<5 mm) and do not improve the detection 
of PCa over tissue biopsies, which remains the gold standard [124]. AA has since been 
demonstrated to detect tortuous microvasculature that correlate with cancer growth in preclinical 
models, which suggests that AA may potentially be more sensitive to detecting malignant PCa 
than conventional CE-TRUS. To test this hypothesis, Li et al designed and developed a dual-
frequency transrectal ultrasound (DF-TRUS) transducer using the stacked-type configuration 
discussed previously. 
 The current DF-TRUS transducer prototype was designed and dimensioned specifically 
for transrectal imaging of the prostate. The normal prostate is within 5 mm from the rectal wall 
and approximately 30 mm x 25 mm in size, however enlarged prostates can grow as large as 50 
mm x 45 mm. The frequency selection was based on an approximate imaging depth of 20-40 
mm. The array consists of 64 low-frequency transmit elements and 128 high-frequency receive 
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elements with center frequencies of 3 and 15 MHz, respectively. The stacked element design 
consists of two high-dielectric constant PZT active layers, separated by an isolation layer and 
flexible circuit. The pitch of the low-frequency transmitting and high-frequency receiving 
elements are 240 µm and 140 µm, respectively. The transducer design was modeled using the 
Krimholtz–Leedom–Matthae (KLM) model finite element analysis, and acoustic field 
simulations were performed using Field II [125,126]. The aperture length is 18 mm, comparable 
to current commercially available TRUS transducers (i.e. Siemens EV-8C4).  
Our hypothesis is that the DF-TRUS transducer can demonstrate comparable SNR and 
CTR compared to a commercially and clinically available prostate transducer, the Siemens EV-
8C4. Our objectives are to perform in-vitro and in-vivo experiments with the DF-TRUS to assess 
the feasibility of AA for PCa imaging. 
 
7.2 Methods 
7.2.i Verasonics Coding 
All DF-TRUS imaging was performed on the Verasonics Vantage 256 system. A custom 
connector was designed and fabricated to adapt the prototype transducer with the Verasonics 
scanhead interface and MATLAB Verasonics scripts were developed for linear array imaging. 
Transmit and receive frequencies were selected at 3.125 MHz and 15 MHz, based on their 
respective center frequencies, and the maximum sampling rate of the Vantage (62.5 MHz) was 
used. 128 transmit ray lines were specified, with 128 corresponding receive events. The synthetic 
aperture size for each transmit ray line was calculated based on the specified focal depth 
(between 10-30 mm) and the F-number (1), and ranged from 10-30 elements.  
 68 
  
 
7.2.ii DF-TRUS Development 
A detailed explanation of the DF-TRUS design and fabrication process has been reported 
previously [127]. Briefly, the design consisted of a dual-layer stack structure with the bottom 
layer containing the low-frequency transmit elements and the top layer containing the high-
frequency receive elements. The high-frequency array can exist on top of the low frequency 
array due to the thin size of the elements, which minimally interferes with acoustic transmission. 
The two layers were separated by an E-Solder 3022 isolation layer to prevent degradation in 
transmit and receive bandwidths due to aliasing echoes. A transmit frequency of 3 MHz was 
chosen to match the resonance frequency of the microbubble contrast agents, and a receive 
frequency of 15 MHz was chosen based on the thickness of the element, which minimizes 
interference with the transmit pulse as well as well providing a sufficient bandwidth separation 
from the transmit elements. Field II and the Krimholtz-Leedom-Matthaei (KLM) model were 
used for testing and design of both transmit and receive apertures, as well as the matching and 
isolation layers.   
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Figure 7. 1. Stacked element design proposed by Li and Kim et al for the dual-frequency linear 
array design. The design consists of high frequency elements stacked on top of the low frequency 
elements, with a matching and isolation layer in between. This is in contrast to the dual-
frequency interleaved element design proposed by Bouakaz et al.  
  
Briefly, for fabrication, a 500 µm PZT plate for the low frequency transmit was attached 
with a top electrode using conductive epoxy. After curing, the epoxy was lapped precisely to 30 
µm in thickness, followed by the bonding of the PZT 2-2 composites receive elements using 
Epo-Tek non-conductive epoxy. The receive layer was then lapped to 100 µm to achieve a 15 
MHz resonance frequency, and then received a top coated of Ti/Au as a conductive layer. After 
dicing the low and high frequency elements to a 280 µm and 140 µm pitch, respectively, the 
array stack was bonded to a flex circuit on both sides and then connected to a printed circuit 
board which would be later used to connect to the Verasonics scanhead interface (Figure 7.2) 
[127].   
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Figure 7. 2. Bottom (left) and side (right) views of the DF-TRUS prototype transducer. The array 
is located on the bottom indicated by the black arrow. A flex circuit couples the array elements to 
printed circuit boards, which connect to a custom adapter cable for the Verasonics Vantage.  
 
7.2.iii Acoustic Characterization 
The transmit waveforms, pressures, and acoustic beam maps were measured for the DF-
TRUS transducer. Measurements were recorded using a needle hydrophone (HNA-0400, ONDA, 
Sunnyvale, CA) connected to an analog-to-digital converter with a sampling rate of 200 MHz. A 
custom LabVIEW program was used to acquire 100 A-lines for measuring the transmit 
waveform and performing voltage vs. pressure calibrations. For beam mapping, the hydrophone 
was mounted to a motorized 3-axis motion stage, and a custom LabVIEW program was built to 
translate the hydrophone in the lateral-axial or the elevational-axial planes. The dimensions of 
the beam maps (axial x lateral) were (1 cm x 1 cm) for both transmit and receive for the DF-
TRUS probe. All beam maps were performed with a step size of 0.125 mm in both dimensions. 
The transmit beam map was measured for the synthetic aperture, and the receive beam map were 
measured for the full aperture. The maximum resolution of each transducer was considered to be 
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the -6 dB full-width half-max (FWHM) of the receive beam maps. Since beam maps could not 
be measured for the EV-8C4 transducer, resolution comparisons were also made measuring on 
imaging the width of a 200 µm cellulose tube (see Section 7.2.vii).  
 
7.2.iv In-Vitro Imaging 
Two in-vitro models were used for measuring SNR and CTR. All measurements were 
repeated with the Siemens EV-8C4 for benchmarking and comparison. The first in-vitro model 
consisted of a 200 µm diameter microcellulose tube bonded to polyethylene (PE20) tubing and 
mounted to an aluminum rod. The tube was suspended in de-ionized water and positioned at the 
focal depth of the transducer (Figure 7.3). The transducer was mounted to and positioned using a 
motorized 3-axis motion stage and controller.  
 
Figure 7. 3. Setup for in-vivo imaging. A 200 µm cellulose tube was suspended in either water or 
tissue mimicking phantom material for measuring SNR or CTR, respectively. The tube was 
infused with microbubble contrast agents. 
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SNR measurements were first recorded at varying transmit pressures ranging from 500-
1000 kPa and calculated based on the unfiltered radio frequency (RF) data using the equation: 
𝑆𝑁𝑅ௗ஻ = 20 × logଵ଴ ൬
𝑉௦௜௚௡௔௟
𝑉௡௢௜௦௘
൰ 
For comparisons between the DF-TRUS and EV-8C4 transducers, SNR was also 
measured based on the image data and normalized to the EV-8C4, as the standard for 
comparison. This second SNR calculation was performed since RF data for the EV-8C4 
transducers were not available. The following equation was used: 
𝑆𝑁𝑅௜௠௚ =
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦௦௜௚௡௔௟
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦௡௢௜௦௘
 
All SNR measurements were acquired with microbubbles infused in the microcellulose 
tube.  
Similarly, the second in-vitro model also consisted of a 200 µm diameter microcellulose 
tube, but was instead embedded in a tissue-mimicking graphite-gelatin phantom (Figure 7.3). An 
acrylic mold was fabricated and the cellulose tube was positioned across the length of the box at 
an angle to make a depth varying (10-25 mm) tube phantom. Once the tube was secured, the 
phantom filler was made and poured into the mold. The phantom filler consisted of 92.5% mL 
DI water, 5% mL n-propanol, and 2.5%  mL Kodak Photo-Flo 2000 (acts as a surfactant to 
produce formation of bubbles), and then 7.5% g/mL of laboratory grade porcine gelatin and 
9.5% g/mL of graphite (acts as ultrasound scatterers). The attenuation of the phantom was 
approximately 0.75 dB/cm/MHz, close to reported values of attenuation for the human prostate 
[128]. A custom imaging bath was used to couple the transducer to the phantom and enable 
translation of the transducer with minimal application of ultrasound gel (Figure 4.1). Images 
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were acquired at varying transmit depths ranging from 5-25 mm and a constant pressure at 
approximately 1.1 MPa, which has been shown previously to produce sufficient superharmonic 
content for AA imaging [56].  
CTR measurements were calculated similarly to the first in-vitro experiment, using two 
equations:  
𝐶𝑇𝑅ௗ஻ = 20 × logଵ଴ ൬
𝑉௠௜௖௥௢௕௨௕௕௟௘
𝑉௧௜௦௦௨௘
൰ 
𝐶𝑇𝑅௜௠௚ =
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦௠௜௖௥௢௕௨௕௕௟௘
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦௧௜௦௦௨௘
 
The equation for CTRdB was consistent with previous work published by Lindsey et al 
and Gessner et al [54,129]. All CTR measurements were made with microbubble contrast agent 
infused in the microcellulose tube. Microbubble contrast agent was diluted 100-fold to an 
approximate concentration of 1x108 bubbles/mL. 
 
7.2.v In-Vivo Imaging 
In-vivo animal imaging was performed with Fisher 344 rats with subcutaneous FSA 
tumors. Please refer to Section 5.2 for details on animal tumor implantation and imaging 
preparation methods. Microbubble contrast agent was diluted in a 1:1 ratio with sterile saline and 
infused at a rate of 40 µm/min, consistent with what was described previously.  
The DF-TRUS transducers was mounted to a 3-axis motion stage (Newport, Irvine, CA) 
which was controlled using a custom LabVIEW program. The rat was positioned underneath the 
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transducer, and coupled with the transducer using ultrasound coupling gel and a custom imaging 
water bath.  
Due to time limitation issues related to data transfer on the Verasonics, a larger step size 
(0.25 mm) was used for the DF-TRUS transducer, compared to what is normally used (0.10 mm) 
with the RMV VisualSonics transducer for AA. This was decided to limit the imaging and 
anesthesia time for the rat while maintaining a 2 cm scan length. A constant transmit pressure of 
approximately 1.1 MPa was used for in-vivo studies. Unprocessed radio-frequency (RF) data 
were removed off of the Verasonics, filtered, and then beamformed offline using Delay-and-Sum 
beamforming.  
 
7.3 Results 
7.3.i Acoustic Characterization Results of DF-TRUS Transducer 
 
Figure 7. 4. Transmit (left) and receive (right) beam maps from the DF-TRUS transducer. The 
resolution of the transducer (210 µm) was determined by the FWHM of the receive lateral beam 
width. 
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The receive resolution of the DF-TRUS transducer, based on the -6 dB point on the 
receive lateral beam profile was measured at 210 µm, and the transmit beam width was measured 
at 640 µm. This is compared to the 130 µm resolution of the RMV probe, reported previously 
[56]. Using the Verasonics Vantage, a transmit voltage of 21.1 V was required to output a 
pressure of 1.07 MPa. Figure 7.5 shows the measured transmit waveform, centered at 3.125 
MHz. For comparison, the RMV probe transmit waveform is provided (Supplemental Figure 
C.3). We can see that the pulse duration is significantly longer. 
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Figure 7. 5. The transmit waveform of the DF-TRUS centered at 3.125 MHz and the 
corresponding frequency spectrum.   
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7.3.ii In-vitro Experiment Results 
All resolution measurements were made using the -6 dB FWHM of the tube cross-
section. The SNRdB of the DF-TRUS 19.25 dB. SNRImg was measured to be 0.86.  
CTRdB measurements from the in-vitro tissue mimicking phantom experiment were 
measured to be 6.9 and CTRImg was measured to be 0.3 (Figure 7.7). The DF-TRUS probe had 
comparable SNRImg compared to the EV-8C4 probe, but considerably lower CTRImg. 
Additionally, the DF-TRUS suffered from poor CTR at depths beyond 1.5 cm (Supplemental 
Figure C.5). All SNR and CTR values are summarized in Supplemental Table D.1.  
 
Figure 7. 6. Lateral and axial resolution measurements of a 200 µm cellulose tube in water 
measured by the DF-TRUS transducer. Dimensions were measured at 1400 µm and 600 µm, for 
the axial and lateral dimensions, respectively. 
 
 The axial resolution is considerably low compared to the lateral resolution, and is likely 
to be caused by the long pulse length of the transmit waveform (Figure 7.4). The DF-TRUS 
resolution is a slight improvement to the EV-8C4, primarily in the lateral dimension. (Figure 
7.6).  
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Figure 7. 7. Lateral and axial resolution measurements of a 200 µm cellulose tube in water 
measured by the EV-8C4 transducer. Dimensions were measured at 1500 µm and 1300 µm, for 
the axial and lateral dimensions, respectively. 
 
 
Figure 7. 8. Images of a 200 µm cellulose tube in a graphite tissue mimicking phantom. The 
bright signal in the lower part of the EV-8C4 image (right) is a specular reflection from the 
bottom of the acrylic mold. The CTRImg measured for the DF-TRUS transducer (left) is 0.3.  
 
7.3.iii In-Vivo Results 
The DF-TRUS transducer was able to detect some microbubble superharmonic signal in-
vivo, with a CTRdB of 3.2 dB (Figure 7.11). The in-vivo model that was used was the inguinal 
area of a rat, a highly vascular region, however the DF-TRUS was only able to detect signal from 
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the largest vessels in the area. While we detect some signal in-vivo, it is below an acceptable 
CTR compared to the EV-8C4. The contrast sensitivity is quite low shown by the inability to 
capture signal from smaller vessels. The vessels measured at approximately 1 mm x 1 mm in the 
axial and lateral dimensions.  
 
Figure 7. 9. 3D representation of the 3D image volume. Left is the B-mode reconstructed image, 
and right is the Acoustic Angiography reconstructed image. Vessels are identified with the white 
arrows. The imaging field was 25 mm x 10 mm x 10 mm (axial x lateral x elevational).  
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7.4 Discussion 
The dual-frequency linear array prototypes described herein, has been demonstrated to 
detect superharmonic microbubble contrast signal in both in-vitro and in-vivo models. However, 
significant improvements are still needed to improve the overall performance. The CTR 
measured in-vivo was less compared to the in-vivo results. There are several potential reasons 
for this which will be discussed. The inguinal area that was imaged is a highly vascular region, 
however we were only able to detect a small number of large vessels, suggesting a very low 
contrast sensitivity. Additionally, a significant amount of tissue signal was present despite 10 
MHz high-pass filtering, suggesting that the improvements can be made to reduce the bandwidth 
of the transmit pulse. 
There are several design limitations that may have affected the imaging performance 
which can be improved in future studies. The array prototype was originally constructed without 
a full backing layer which we suspect affected the transmit bandwidth. From Figure 7.5, we can 
also see that the pulse length of the DF-TRUS transducer is significantly longer (2x) than the 
RMV (Supplemental Figure C.3) probe, reducing axial resolution and transmission sensitivity. 
Adding a backing layer will likely decrease harmonic content while shortening the pulse.  
The reason for the discrepancy between the in-vitro and in-vivo CTR is likely that the 
microbubble concentration used for in-vitro experiments was greater than what was used in-vivo. 
Additionally, the elevational foci of the transmit and receive arrays were largely separated (~40 
mm separation), reducing the alignment of the focused beams. This mismatch results in a wider 
elevational beam and may have affected vessel detection of less linear vessels in-vivo (in 
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contrast to the straight tube used in-vitro). The electrical wiring may have also contributed to 
system and image noise. Since a custom Verasonics adapter was manually soldered, many of the 
wires were not completely shielded and unconnected wires were sealed but not insulated. It was 
hypothesized that the Verasonics pulse driving sequence could be improved to reduce the pulse 
length of the transmit waveform, however no improvements could be made. A shorter single 
cycle pulse was both simulated and achieved, however this produced even higher frequency 
content than before.  
A linear array design was preferred for the DF-TRUS prototype since it is easier to 
design and implement. However one of the disadvantages for linear array imaging is a limited 
field of view for imaging. The current design has an aperture size of approximately 18 mm. This 
field of view is significantly limited and is not sufficient for imaging prostates that are frequently 
enlarged beyond 200 cc (4-6 cm) from BPH or PCa. The aperture is comparable to the EV-9C4 
transducer, however the Siemens probe operates as a curvi-linear array. Phased array imaging 
may be a better alternative for enlarged prostate imaging. Additionally, a lower transmit and 
receive frequency combination can be used for increased penetration. In fact, Lindsey et al 
determined that maximum superharmonic energy is generated with a transmit frequency of 2 
MHz and a maximum CTR is achieved with a receive frequency of 10 MHz [129]. Future 
iterations of the DF-TRUS design will be improved upon based on these recommendations.   
While the image quality of the DF-TRUS cannot yet be compared to the commercially 
available EV-8C4 transducer, the initial in-vitro results coupled with the fact that there are 
achievable improvements that can be made to in future design iterations are promising for 
significantly improving the performance.  
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7. 5 Conclusions 
There is a potential need for improved PCa detection and biopsy guidance using 
ultrasound imaging. Current ultrasound techniques (b-mode and CEUS) suffer from low 
specificity to PCa malignancy. AA is sensitive to measuring differences in tumor 
microvasculature compared to normal tissue and it is also sensitive to measure changes in certain 
microvascular features. This technology has the potential to improve the specificity of diagnosis 
and ultrasound guided prostate biopsy. 
Despite many successful preclinical studies, clinical translation of AA requires the 
transition to an array-format type transducer for increased depth of penetration and faster image 
acquisition. The prototype DF-TRUS transducer is the first dual-frequency transducer of the 
stacked configuration type for superharmonic imaging and the results from the first design 
iteration of the array are promising. The work described in this chapter intends to bring AA one 
step closer to clinical use.   
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CHAPTER 8: 
Proof of Concept Dual-Probe/Dual-Frequency Transducer for AA 
 
8.1 Overview 
We previously demonstrated the feasibility of using a stacked type design for linear 
arrays for performing AA. Although initial in-vivo results demonstrated low CTR and contrast 
sensitivity, there is significant room for improving the design and imaging performance in future 
iterations. However, since linear array transducer manufacturing is challenging in a laboratory 
setting, it is difficult to fully assess the potential of dual-frequency, linear array AA and its 
benefit over conventional CEUS.  Difficulties in array fabrication and electrical shielding of the 
electronic components results in lower SNR and potentially can be avoided in a commercial 
setting. In order to better assess this advantage, we will demonstrate a proof-of-concept dual-
probe/dual-frequency (DP-DF) for superharmonic imaging using two separate commercially 
available linear arrays transducers. This new proof-of-concept may help in modifying design and 
imaging specifications for the future redevelopment of the DF-TRUS transducer described 
previously. Therefore, the primary objectives are 1) to demonstrate the full potential for linear 
array dual-frequency for superharmonic imaging in in-vitro and in-vivo model and 2) compare 
the performance to both the Siemens EV-8C4 transducer, and the RMV probe used previously 
for all pre-clinical AA imaging. 
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8.2 Methods 
8.2.i Verasonics Coding 
For DP-DF imaging, two Verasonics systems were used. First, a Verasonics V1 system 
was used for the low frequency transmit, and a Verasonics Vantage 256 was used for the high-
frequency receive. The transmit and receive frequencies were selected at 2.5 MHz and 15.625 
MHz, respectively, with a maximum sample rate of 62.5 MHz. 77 transmit ray lines were 
specified based on the lateral transmit beam width, with 77 corresponding receive events. The 
transmit coordinate system was based on the high frequency transducer aperture. The synthetic 
aperture size for each transmit ray line was calculated based on the specified focal depth 
(between 10-30 mm) and the F-number (1), and ranged from 10-30 elements. The linear array 
imaging sequence was the same for both DF-TRUS and DP-DF. MATLAB Verasonics scripts 
were developed for linear array imaging using both transducers.  
 
8.2.ii DP-DF Set-up 
The DP-DF transducer consisted of two commercially available transducers, 
mechanically clamped so that their transmit/receive beams overlapped at a specified acoustic 
focus.  An ATL P4-1 linear phased array transducer was used as the low frequency transmit 
array, and a VisualSonics MS250 linear array transducer was used for the high frequency receive 
array.  
Each transducer was digitally scanned using a NextEngine 3D laser scanner (NextEngine, 
Santa Monica, CA), and then custom molded clamps were designed using the computer-aided 
design software (SolidWorks, Dassault Systèmes, Waltham, MA) and 3D printed on a uPrint SE 
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(Stratasys, Prairie, MN). The transducers were angled at 30.78° in order to converge their 
transmit/receive beams at approximately 25 mm (Figure 8.1).  
 
 
The P4-1 and MS250 transducers have 96 and 256 elements, respectively. Due to the 
large number of elements, two Verasonics systems were necessary for DP-DF imaging; a 
Verasonics V1 system was used for low frequency transmit, and a Verasonics Vantage 256 
system was used for high frequency receive. A Universal Transducer Adapter (UTA) with 360 
pins was used to interface the MS250 with the Vantage system.  
8.2.iii Acoustic Characterization 
The transmit waveforms, pressures, and acoustic beam maps were measured for the DP-
DF transducers. Waveform measurements and beam mapping were recorded using a needle 
hydrophone, similar to what was described in Section 7.2.iv. The dimensions of the beam maps 
(axial x lateral) were (1 cm x 3 cm) and (0.5 cm x 0.5 cm) for transmit and receive, respectively, 
for the DP-DF probe. All beam maps were performed with a step size of 0.125 mm in both 
Figure 8. 1. 3D modeling of the transmit and receive transducers for the DP-DF configuration. 
An angle of approximately 38 degrees ensured the foci of both transducers overlapped around 
2.5 cm in depth. The design is programmed to be adjusted for any desired depth imaging. In the 
future, additional depths will be trialed (>5-6 cm).  
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dimensions. The transmit beam map as measured for the synthetic aperture, and the receive beam 
map was measured for the entire aperture. The maximum resolution of the transducer was 
considered to be the -6 dB FWHM of the receive beam width. All measurements were repeated 
for the RMV probe. Since beam maps could not be measured for the EV-8C4 transducer, 
resolution comparisons were also made measuring on imaging the width of a 200 µm cellulose 
tube (see Section 8.2.vii).  
 
8.2.iv In-Vitro Imaging 
Two in-vitro models were used for measuring SNR and CTR. All measurements were 
repeated with the Siemens EV-8C4 and Vevo 770 RMV transducers for benchmarking and 
comparison. The first in-vitro model consisted of a 200 µm diameter microcellulose suspended 
in water, and the second model consisted of a second microcellulose tube suspended in a tissue 
mimicking graphite-gel phantom (consistent to what was described previously in Chapter 7). 
SNRdB and CTRdB measurements for the DP-DF transducer were calculated by the filtered RF 
data, and was compared to SNRImg and CTRImg measured by the EV-8C4 and RMV image data, 
as previously described. 
All SNR and CTR measurements were made with microbubble contrast agent infused in 
the microcellulose tube. Microbubble contrast agent was diluted 100-fold to an approximate 
concentration of 1x108 bubbles/mL. 
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8.2.v In-Vivo Imaging 
In-vivo animal imaging was performed with Fisher 344 rats with subcutaneous FSA 
tumors. Please refer to Section 5.2 for details on animal tumor implantation and imaging 
preparation methods. Microbubble contrast agent was diluted in a 1:1 ratio with sterile saline and 
infused at a rate of 40 µm/min, consistent with what was described previously. Imaging was 
performed on two consecutive days (DP-DF on the first day, and EV-8C4/RMV on the second 
day) as to limit the total contrast dose and anesthesia time for the rat.  
The EV-8C4 and DP-DF transducers were mounted to a 3-axis motion stage (Newport, 
Irvine, CA) which was controlled using a custom LabVIEW program. The RMV probe was 
controlled using the Vevo 770 system which has its own precision motion stage (VisualSonics, 
Toronto, CA). The rat was positioned underneath the transducer, and coupled with the transducer 
using ultrasound coupling gel and a custom imaging water bath. Table 7.1 summarizes the 
imaging parameters for each imaging system.  
Table 7. 1 In-vivo Imaging Parameters 
 RMV DP-DF EV-8C4 
Elevtational Step Size (mm) 0.100 0.25 0.25 
Scan Length 
(mm) 
20 20 20 
Frame Averaging 2 2 0 
Frame Rate  
(Hz) 
3 7 14 
# of Tx Ray Lines  77 unknown 
Tx Focus 
(mm) 
16 25 25 
 
Due to time limitation issues related to data transfer on the Verasonics, a larger step size 
(0.25 mm) was used for DP-DF transducers compared to the RMV transducer (0.10 mm) to limit 
the imaging time while maintaining a 2 cm scan length. A constant transmit pressure of 
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approximately 1.1 MPa was used for both the DP-DF and RMV transducers (except for the EV-
8C4—the transmit pressure was unknown). The  DP-DF unprocessed radio-frequency (RF) data 
were removed off of the Verasonics, filtered, and then beamformed offline. Image data was 
directly taken from the Vevo 770 and Sequoia scanners for the RMV and EV-8C4 transducers, 
respectively.  
 
8.2.vi Image Processing and Analysis 
DP-DF RF data were filtered using a finite-impulse response high-pass filter with a cut-
off frequency at 10 MHz and beamformed using the Delay-Multiply-And-Sum (DMAS) 
technique [130]. Since RF data was not available for the RMV and EV-8C4 probes for signal 
based CTR measurements, CTR was alternatively measured based on image intensity dividing 
the signal intensity of contrast perfused tissue by the baseline tissue noise, and normalized to the 
EV-8C4, which was used as the standard for comparison.  
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8.3.  Results 
8.3.i Acoustic Characterization Results 
 
Figure 8. 2. Transmit (left) and receive (right) beam maps from the DP-DF transducer. The 
resolution of the transducer (220 µm) was determined by the FWHM of the receive lateral beam 
width. 
 
The receive resolution of the DP-DF transducer was measured at 220 µm, and the 
transmit beam width was measured at 950 µm (Figure 8.2). Using the Verasonics V1, a transmit 
voltage of 28.2 V was required to output a pressure of 1.04 MPa. A co-alignment beam map 
shows that the beams intersect approximately at 35 mm (Figure 8.3).  
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Figure 8. 3. An alignment beam map of the DP-DF transducer in the elevational-axial plane. The 
true focus of the transducer is closer to 35 mm from the faces of the transducers. The wide 
elevational beam width is apparent.  
 
From the co-alignment beam map, we can see that the elevational beam profile of the low 
frequency P4-1 transducer has two significant side lobes, with slightly less pressure in the main 
lobe (1.5 dB less). The transmit waveform of the DP-DF transducer, centered at 2.5 MHz is 
shown in Figure 8.4.  
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Figure 8. 4. The transmit waveform of the DP-DF transducer centered at 2.5 MHz and the 
corresponding frequency spectrum.   
 
8.3.ii In-vitro Experiment Results 
In the first in-vitro setup while in contrast imaging mode, the 200 µm cellulose tube was 
measured [laterally, axially] to be [1400 µm, 600 µm], [500 µm, 500 µm], and [1300 µm, 1500 
µm] by the DP-DF, RMV, and EV-8C4 transducers, respectively. All measurements were made 
using the -6 dB FWHM of the tube cross-section. The SNRdB of the DP-DF transducer was 
measured to be 24.05 dB, respectively. SNRImg was measured to be 3.66 and 2.6, for the DP-DF 
and RMV probes, respectively.  
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CTRdB measurements from the in-vitro tissue mimicking phantom experiment were 
measured to be 16.6 dB with the DP-DF transducer. CTRImg was measured to be 1.1, and 2.2 for 
the DP-DF, and RMV transducers, respectively. The DP-DF transducer measured the highest 
SNR compared to the other three transducers and displayed comparable CTR with previously 
reported CTRdB values for the RMV probe. All SNR and CTR values are summarized in 
Supplemental Table D.1.  
 
8.3.iii In-vivo Results 
Tumor images from the DP-DF, RMV, and EV-8C4 transducers are shown Figures 8.5 
and 8.7). The RMV transducer produce an image consistent with previous studies, with vessels 
as small as 200 µm being detected and a CTRImg of 4.5. The EV-8C4 image shows exceptional 
contrast sensitivity as seen by the ability to detect contrast signal in the center of the tumor, 
however lower CTR, as seen by the baseline (non-contrast) image (Figure 8.5). The DP-DF also 
showed high contrast sensitivity and low tissue signal, with a CTRImg of 1.53. The DP-DF images 
showed in Figures 8.5 and 8.7 are temporally compounded with 2 frame averaging. When we 
compare frame averaging with a single, no averaged slice, we see significant contrast sensitivity, 
specifically in the middle of the tumor, comparable to the EV-8C4 transducer (Figure 8.6).  
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Figure 8. 5. In-vivo images from the DP-DF, RMV, and EV-8C4 transducers. B-mode, baseline, 
and contrast infused images are shown to compare differences in CTR and contrast sensitivity.  
 
3D reconstruction and maximum intensity projection (MIP) of the image stacks acquired 
by the DP-DF transducer shows clear vessel structure that agree with the RMV images. The 
smallest vessel detectable by the RMV and DP-DF transducers was 175 µm and 320 µm, 
respectively. Upon closer examination, we can clearly identify common vessels in both coronal 
MIPs.  
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Figure 8. 6. A Comparison of frame averaging versus no frame averaging using the DP-DF 
transducer. The 0-frame averaging image shows comparable contrast sensitivity to in regions not 
detected after significant frame averaging or by the RMV probe.  
 
Figure 8. 7. MIPs of the DP-DF probe compared with the RMV probe of the same FSA tumor. 
Identical vessels can be identified in both of the coronal MIPs. The elevational resolution is 
significantly less for the DP-DF transducer due to the larger step size (0.25 mm vs 0.1 mm), and 
the wide transmit beam width. 
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8.4 Discussion and Conclusions 
Since many of the manufacturing limitations in a laboratory environment described in 
Chapter 7, which likely impacted the performance of the DF-TRUS transducer, can be solved in 
a commercial environment (i.e. application of a lens to account for varying elevational foci, 
design of a small form-factor electrical adapter, etc) it is difficult to fairly assess the full benefit 
of linear array superharmonic imaging. As a supplement to the DF-TRUS probe, we 
demonstrated a proof-of-concept “dual-frequency linear array” by using two separate 
commercially available transducers. The usefulness of this approach is that we can better assess 
the capability of linear array imaging by removing manufacturing limitations out of the equation. 
The frequencies for the DP-DF transducer were selected similarly to the DF-TRUS, 
except with a lower transmit frequency (2.5 MHz) to maximize the transmit sensitivity of the P4-
1 transducer. The center frequency of the receive transducer was approximately 6 harmonics 
above the transmit frequency. The configuration of the transducers was such that a single fixed 
focus was required (which made multi-focus imaging impossible with the current design). A 
focus of 2.5 cm was chosen to so that we can demonstrate deeper imaging capability compared 
to the RMV probe, which is limited to 1.5 cm. We have yet to demonstrate feasible imaging 
depths relevant for prostate imaging. However, the alignment beam map showed that the true 
aligned depth of both transducers was closer to 3 cm, deeper than we had designed for. At these 
imaging parameters we were able to detect and resolve vessels in-vivo, which to our knowledge, 
has not been previously demonstrated using linear array superharmonic imaging. While we 
stayed fixed within 3 cm for DP-DF imaging, we can clearly see improved depth of field 
compared to the RMV transducer, specifically at the top and bottom regions of the tumor (Figure 
8.7).  
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As a proof-of-concept, these results are very promising and certain fundamental 
limitations in the design can be easily improved upon in future iterations to achieve higher 
resolution and greater CTR. First, the low frequency transducer was a linear phased array probe 
programmed to image in linear array mode. Since it is designed for phased array imaging, the 
natural focus is significantly deeper compared to the high frequency receive. The alignment 
beam map clearly shows the wide elevational beam width with large side lobes. This 
significantly reduces the transmit sensitivity at the desired focus of 25 mm. Additionally, for 
deeper imaging we lose receive sensitivity of the high frequency transducer due its shallow 
elevational focus. It will be challenging in future iterations to find both low and high frequency, 
commercially available transducers with matched elevational foci. A potential solution might be 
to offset the low frequency transducer to match the maximum elevational focus of the high 
frequency transducer, however this will further increase the transmit beam width laterally, 
reducing contrast sensitivity.  
The Verasonics imaging scripts can also be improved to drastically speed up the imaging 
procedure, allowing us to capture more slices with a finer elevational step size, and more frames 
per slice for temporal averaging and/or angular compounding. This amendment will improve 
elevational and lateral resolution, as well as CTR. While we have demonstrated preliminary 
capabilities that this proof-of-concept dual frequency array can perform microvascular imaging, 
for prostate imaging the challenge still exists that both sets of arrays eventually will need to be 
co-aligned and in the form factor for transrectal imaging.  
As mentioned previously, while the stacked type configuration is a novel approach for 
superharmonic imaging that holds promise for realizing linear array AA, an alternative approach 
to AA for high-resolution microvascular imaging is ultrasound localization microscopy. This 
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CEUS approach requires only a single linear array and promises resolution beyond the 
diffraction limit of ultrasound [106,131]. While the design specifications for super resolution 
imaging may be simpler, the disadvantages lie in the significantly long image acquisition times 
for volumetric imaging due to the large number of frames (>1000) required for a single slice. 
Until the image acquisition times can be shortened for super resolution imaging (either by faster 
frame rates or development of higher resolution 2D arrays for CEUS), the dual-frequency linear 
array approach appears to be the most promising for clinical translation of high-resolution 
microvascular imaging.  
While high-resolution microvascular imaging may be beneficial for prostate imaging, due 
to the required depth of penetration (4-6 cm), we begin to be challenged by the trade-off between 
imaging depth and imaging frequency. With increased imaging depth we require lower transmit 
and receive frequencies and therefore sacrifice resolution. Fortunately, with AA, there is only 
one-way high frequency attenuation (on receive) since the transmit frequency is designed to be 
low and experiences less attenuation. Based on preliminary data that we can detect microbubble 
signal as deep as 6.5 cm using the DP-DF configuration at 15.625 MHz, we can theoretically 
achieve imaging depths of up to 9.75cm if we reduce our receive frequency to 10 MHz. As 
mentioned previously, maximum superharmonics are generated with a transmit frequency of 2 
MHz and a maximum CTR is achieved with a receive frequency of 10 MHz [129]. In the future, 
choosing two transducers within these frequency combinations might allow us to further improve 
microbubble detection at depth.  
To date, the ability to achieve resolutions for detecting individual vessels at depths 
greater than 4 cm is yet to be determined. Even so, the technique for superharmonic imaging is 
inherently more sensitive to microbubble contrast signal than conventional CEUS techniques, 
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which may prove to be beneficial in detecting changes in tissue perfusion with higher sensitivity 
even without the resolution of what we are used to seeing with AA.  
 
8.5 Future Work 
In addition to reiterating of the DF-TRUS prototype design, investigating a clinically 
relevant prostate tumor model with AA will give insight into what types of microvascular 
information is most important for both prostate lesion detection and malignant cancer diagnosis, 
and may help tailor the development of DF-TRUS. A pre-clinical tumor model, the Dunning 
R3327-AT2 rat prostate tumor grown in Copenhagen rats, is a slow growing, androgen 
dependent tumor model which has been shown to be an appropriate model for PCa research 
[132,133].  
As stated previously, increased depth of penetration using AA imaging has yet to be 
demonstrated. Current work is in progress for determining the maximum depth (>6.5 cm) at 
which the DP-DF configuration can detect microbubble contrast signal with relevant SNR and 
CTR values.  
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APPENDIX A: 
A Quantitative Approach to Characterizing Malignant Renal Cell Carcinoma Using 
Contrast Enhanced Ultrasound2 
 
A.1 Introduction 
Renal cell carcinoma (RCC) affects approximately 1 in every 100 American individuals, 
with an estimated 62,000 new cases to be diagnosed in 2016 in the United States alone [134]. 
Classification of RCC has evolved over the last three decades, leading to four main subtypes: 
clear cell, papillary type I, papillary type II, chromophobe. Clear cell RCC is the most common 
(~75%) type of RCC, followed by papillary (~16%) and chromophobe (~7%). Each of these 
tumors has been recently characterized genetically by the cancer genome atlas, underscoring the 
unique biology of each disease type [135–137]. RCC classification is a critical diagnostic step 
since clinical management is based on the varying prognoses and therapeutic pathways of each 
subtype [138].  Clear cell and papillary type II RCCs have a higher probability of metastasizing 
even after nephrectomy for organ-confined tumors, while the prognosis for papillary type I and 
chromophobe RCCs are significantly better and are therefore managed more conservatively 
compared to clear cell RCC [139,140]. Radiographic distinction between these malignant RCC 
subtypes is inherently difficult due to molecular aberrations and structural contributions that lead 
to shared tumor morphology [141].  
                                                 
2 This chapter previously appeared as an article in the Journal of Ultrasonic Imaging. The original citation is as 
follows:  Kasoji SK, Chang EH, Mullin LB, Chong WK, Rathmell WK, Dayton PA. A Pilot Clinical Study in 
Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound. Ultrason 
Imaging. 2017;39(2):126-136. 
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Traditional gray-scale ultrasound is effective for differentiating solid from cystic kidney 
lesions, but lacks the sensitivity to further classify solid masses according to histologic type. 
Contrast-enhanced computed-tomography (CT) and magnetic resonance imaging (MRI) are the 
standard imaging exams used to assess the malignancy of solid masses and to characterize 
perfusion patterns; however, the contrast sensitivity does not adequately resolve histologic 
characteristics of many types of tumors arising in the kidney, including hypovascular and cystic 
lesions, necrosis, debris and hemorrhagic areas in tumors [142]. Additionally, the nephrotoxicity 
of the contrast agents often limits their use [143]. Thus, tissue analysis, often post-nephrectomy, 
has remained the gold standard for identifying RCC subtypes despite the invasive nature of the 
procedure. 
Recent clinical studies have shown that contrast-enhanced ultrasound (CEUS), a non-
nephrotoxic and non-ionizing imaging modality, has the ability to assess malignancy of solid and 
cystic kidney lesions based on qualitative enhancement and perfusion patterns [144]. Only a few 
studies, however, have considered quantitative approaches to further characterize RCC subtypes 
[140,145–148]. In this study, we quantify perfusion patterns in 12 patients diagnosed with kidney 
masses and correlate specific metrics with pathologic findings.  
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A.2 Materials and Methods 
A.2.i Patient Recruitment and Initial Tests 
University of North Carolina’s Institutional Review Board approved this study and 
written informed consent was obtained from each patient prior to the study. Over a two-year 
period, twenty-four individuals diagnosed with kidney lesions were recruited for the study and 
imaged with contrast-enhanced ultrasound (CEUS). All patients were imaged using traditional 
ultrasound and either CT or MRI prior to CEUS, and tissue biopsy or resection was performed 
on 22 of the 24 patients post-CEUS. Histologic analyses were performed on all 22 patients and 
classified by expert clinical pathologists as clear cell RCC (ccRCC, n=15), papillary RCC 
(pRCC, n=3), chromophobe RCC (chRCC, n=2), angiomyolipoma (AML, n=1), or oncocytoma 
(OCT, n=1). AMLs and OCTs were excluded from the study as benign tumors. Eight of the 
twenty-two patients were excluded from quantitative analysis due to poor video quality caused 
by excessive out-of-plane motion (displacement greater than half the size of the lesion of 
interest) and inadequately visible parenchyma (less than a 5 mm2 ROI).  Therefore, the 
remaining 12 were included in the final analysis. Two patients underwent core biopsies, while 
the remaining 10 underwent partial or complete nephrectomy. 
 
A.2.ii Contrast-Enhanced Ultrasound 
CEUS imaging was performed on a Siemens/Acuson Sequoia 512 (Mountain View, CA, 
USA) by a trained sonographer. Traditional b-mode ultrasound clips were first recorded for each 
patient to determine the anatomical location and dimensions of the lesion.  The transducer was 
optimally positioned so that the lesion and normal parenchyma (renal cortex) were clearly visible 
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and so that breathing motion was maintained within the plane. After the sonographer localized 
the lesion of interest and was able to maintain a consistent image along with patient breathing, a 
mechanical stereotactic clamp was fixed to maintain the transducer position. The clamp was 
introduced to help minimize sonographer hand motion during acquisition of the cine loop and to 
alleviate physical cramping of the wrist during the long imaging period. The depth and spacing 
of the imaging foci were adjusted to the center on the lesion based on the lesion size and depth. 
Cadence Pulse Sequence (CPS) mode was used for contrast imaging at a mechanical index (MI) 
of 0.19. A 5 mL bolus injection of the diluted microbubble contrast agent, Definity (Lantheus, 
North Billerica, MA, USA), was administered through the antecubital vein over 15 seconds, 
followed by a 5 mL flush of 0.9% saline. Contrast dose was based on patient weight (0.5 mL for 
<125 lb, 0.65 mL for 125-185 lb, 1.0 mL for >185 lb). Image acquisition was initiated 
immediately prior to the bolus injection and ended after 3 minutes, capturing contrast wash-in 
and at least 2 minutes of contrast wash-out.  
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A.2.iii CEUS Time-Intensity-Curve Analysis 
 
Figure A. 1. Ellipsoidal ROI selection of both the lesion (red) and normal renal cortex (blue). 
ROIs were draw with a minimum diameter of 5mm, and parenchyma and lesion ROIs were 
drawn at approximately the same depth (±1 cm). 
 
DICOM files containing the b-mode and contrast clips were copied from the Sequoia 512 
and converted to audio-video interleave files for subsequent analysis using ImageJ (National 
Institutes of Health, Bethesda, MD, USA) and MATLAB (MathWorks, Natick, MA, USA). 
Clips that contained severe out-of-plane breathing and body motion were omitted from 
quantitative analysis. In the instances where breathing motion was regular and cyclic, a targeted 
ROI for the lesion and parenchyma was selected whenever it appeared in plane. Rigid image 
registration was performed using the StackReg plugin for ImageJ to correct in-plane breathing 
motion. Ellipsoidal regions-of-interest (ROI) with a minimum diameter of 5 mm were selected 
for the lesion and the renal cortex separately at approximately the same depth (±1 cm) (Figure 
A.1).  
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Lesion ROIs were selected to encompass the entire lesion excluding the normal 
parenchyma. Time-intensity-curves (TIC) were generated for all ROIs. Any cystic and necrotic 
regions that were present were excluded in the ROI selection. Residual breathing motion was 
further removed by filtering the TICs in MATLAB using a low pass filter (f-3dB = 0.025 Hz). Ten 
metrics were applied to each of the TICs, including peak contrast intensity (PI), time-to-peak 
(TPk), time-to-peak ratio (TPk-r), time-to-80% on wash-out (T80%), time-to-80% on wash-out 
ratio (T80%-r), wash-in slope (WIS), wash-out slope (WOS), wash-in ratio (WIS-r), wash-out 
ratio (WOS-r), and wash-in/wash-out ratio (WIWOS-r). The metrics are described below and 
graphically summarized in Figure A.2 and Table A.1. Time-to-80% was estimated based on the 
inflection point of the decay phase of the gamma variate function (𝑦 = 𝐴 ∙ 𝑡 ∙ ൫1 −  𝑒ିఉ௧൯ + 𝐶), 
which is approximately at 75% of the peak intensity. Peak contrast intensity was measured with 
non-normalized data, which is not shown in Figure A.2. 
  
 104 
  
Table A. 1. Definitions for metrics used for TIC analysis. 
Metric Definition 
Peak contrast intensity ratio Ratio of peak intensity (lesion/parenchyma) 
Time-to-peak Time to peak intensity of lesion 
Time-to-peak ratio Ratio of time to peak intensity 
(lesion/parenchyma) 
Time-to-80% Time from peak intensity to 80% on wash-out 
for lesion 
Time-to-80% on wash-out ratio Ratio of the time from peak intensity to 80% on 
wash-out (lesion/parenchyma) 
Wash-in slope Wash-in slope of lesion 
Wash-out slope Wash-out slope of lesion 
Wash-in ratio Ratio of wash-in slopes (lesion/parenchyma) 
Wash-out ratio Ratio of wash-out slopes (lesion/parenchyma) 
Wash-in/Wash-out ratio Ratio of wash-in to wash-out of lesion 
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Figure A. 2. Sample TICs of a lesion (red) and renal cortex (blue). The raw data is filtered and 
smoothed through software filtering. Wash-in/wash-out slopes are calculated, and time-to-peak 
and time-to-80% wash-out are calculated based on the filtered curves. 
 
A.2.iv Histological Analysis 
Histologic tissue diagnoses for resected (N=10) or biopsied (N=2) tissues were obtained through 
routine clinical reports at the University of North Carolina at Chapel Hill, Department of 
Surgical Pathology. Diagnosed lesion subtypes included chromophobe RCC, clear cell RCC, and 
papillary RCC.  
 
A.2.v Statistical Analysis 
Statistical analyses were performed using MATLAB (MathWorks, Natick, MA, USA) 
and R-Studio (R Foundation for Statistical Computing, Vienna, Austria)[149]. For each metric, 
results were grouped by cancer type. One-way ANOVA was performed for each metric and the 
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Tukey-Kramer multiple-comparison test was used to determine significant differences between 
each group.  
 
A.3 Results 
Twelve final CEUS clips qualified for TIC analysis based on image quality—clips with 
excessive out-of-plane motion or clips with inadequately visible parenchyma were excluded. The 
pathological findings for the twelve patients showed presence of 2 papillary RCC, 8 clear cell 
RCC, and 2 chromophobe RCC. Lesion sizes ranged from 1.72 cm to 7.50 cm in the longest 
dimension (3.75 cm ± 1.57 cm).   
One-way ANOVA statistical test results for each metric are summarized in Table 2. 
Significant differences with a 95% confidence interval between groups were observed using the 
peak intensity ratio (Figure A.3) with p=0.001 (p=0.001 between clear cell and papillary RCCs, 
and p=0.04 between chromophobe and papillary RCCs) and time-to-80% ratio metric (Figure 
A.4) with p=0.004 (p=0.020 between chromophobe and clear cell RCCs, and p=0.003 between 
chromophobe and papillary RCCs). The PI metric measured the lowest lesion-to-parenchyma 
ratio for papillary RCC (0.57 ± 0.24), followed by chromophobe RCC (0.92 ± 0.03), and clear 
cell RCC (1.1 ± 0.1). The time-to-80% ratio metric also measured the lowest lesion-to-
parenchyma ratio for papillary RCC (0.35 ± 0.33), followed by clear cell RCC (0.68 ± 0.16), and 
chromophobe (1.14 ± 0.05). All other metrics did not measure significant differences (p>>0.05) 
(Table 2).  
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Table A. 2. Results from ten metrics derived from lesion and parenchyma TICs 
Metric P-value 
(*p<0.05) 
P-value 
(cc v p) 
P-value 
(cc v ch) 
P-value 
(p v ch) 
Peak Intensity ratio (PI) 0.001* 0.001 0.18 0.04 
Time to Peak (TPk) 0.851 --- --- --- 
Time to Peak ratio (TPk-r) 0.978 --- --- --- 
Time to 80% (T80%) 0.065 --- --- --- 
Time to 80% ratio (T80%-r) 0.004* 0.08 0.02 0.003 
Wash-in Slope (WIS) 0.957 --- --- --- 
Wash-out Slope (WOS) 0.910 --- --- --- 
Wash-in Slope ratio (WIS-r) 
(lesion/parenchyma) 
0.890 --- --- --- 
Wash-out Slope ratio (WOS-r) 
(lesion/parenchyma) 
0.155 --- --- --- 
Wash-in/Wash-out Slope ratio 
(WIWOS-r) 
0.866 --- --- --- 
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Figure A. 3. (left) Peak intensity ratio results. Papillary RCC measured 0.57 ± 0.24, 
chromophobe RCC measured 0.92 ± 0.03, and clear cell RCC measured 1.1 ± 0.1. The papillary 
RCC PI ratio was significantly different from clear cell (p=0.001) and chromophobe (p=0.04) 
ratios. (right) Time-to-80% ratio results. Papillary RCC measured 0.35 ± 0.33, chromophobe 
RCC measured 1.14 ± 0.05, and clear cell RCC measured 0.68 ± 0.16. The chromophobe RCC 
time-to-80% ratio was significantly different from clear cell (p=0.02) and chromophobe 
(p=0.003) ratios. 
 
A.4 Discussion 
Previous studies have demonstrated the utility of qualitative and quantitative CEUS 
perfusion analysis (including TIC analysis) for distinguishing solid from cystic kidney masses 
and malignant from benign solid masses [145,146]. Solid masses, including most RCCs, and 
oncocytomas, typically appear hypoechoic on traditional b-mode ultrasound. Other solid lesions, 
such as angiomyolipomas typically appear hyperechoic due to their fatty content, but may 
sometimes also appear hypoechoic. CEUS has been shown to be a viable option in these cases 
where malignancy is unclear and contrast MR/CT are contraindicated. The focus of our study is 
to further discriminate between RCCs given the varying prognoses and treatments for each 
subtype. Pre-surgical knowledge of the suspected histological type of tumor would benefit 
 109 
  
patients and health-care providers in making decisions about interventions, therapy, or clinical 
management approaches that incorporate careful observation. Several studies have recently 
emerged that quantify perfusion patterns of RCC subtype [140,143,145,146,150].  
King et al. reported a similar TIC analysis and concluded that some metrics are better 
suited for certain types of kidney lesions [146]. For example, ccRCC enhances more than the 
surrounding parenchyma and has a faster time-to-peak (TPk), while pRCC enhances less than the 
parenchyma and has a slower TPk. chRCC was shown to have intermediate peak enhancement 
and TPk between ccRCC and pRCC. Metrics such as homogeneity of enhancement and rate of 
de-enhancement were shown to be more relevant to angiomyolipomas and oncocytomas [146].  
Results for wash-in slope, wash-out slope, and TPk analyses have largely been 
inconsistent across previously published studies. This may be due to technical variations of the 
imaging and analysis technique and physiologic differences in the tumor. In all cases, lesion 
perfusion characteristics were compared to the renal cortex. Consistency in imaging depth has a 
significant impact on relative enhancement measurements between normal and diseased tissue 
due to attenuation. Also, heterogeneity of RCCs at different stages of development may induce 
user error by choosing a cross-section that is not entirely representative of the entire mass. It is 
also important to consider that many studies do not distinguish between histologies and are 
focused instead on the feature that distinguish benign from malignant disease. Some results 
report that all malignant RCCs display a fast wash-in, while others describe pRCC with a slower 
wash-in [143,145,146,150]. We observed that many TICs, especially for pRCC, exhibited a bi-
phasic wash-out—a steeper initial wash-out of the contrast bolus injection, followed by more 
gradual clearance of the recirculating contrast. The gamma-variate fit is commonly used to 
model kidney perfusion, which is estimated by a left-skewed Gaussian curve with an 
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exponentially decaying tail [151].  The point of inflection on the downslope occurs 
approximately at 75% of the peak intensity, which happened to be near the beginning of the 
second phase of wash-out. Although our TICs did not conform to the gamma-variate fit as well 
as other studies have shown, we chose 80% to be our threshold to measure the start of the second 
phase of contrast wash-out. Cai and King used 60% and 50%, respectively, which we observed 
to be during the second phase of wash-out [145,146]. We believe that the bi-phasic wash-out 
pattern is of clinical importance, and measuring the time interval between phases may be a 
method of describing this pattern. Other perfusion models (e.g. Karshafian et al.’s lognormal 
perfusion model) that describe contrast replenishment during destruction-reperfusion imaging, 
can extrapolate information related to the distribution of flow speeds, vascular size and 
morphology, and blood volume. Burns et al. exquisitely describe the value of choosing an 
appropriate perfusion model for enabling versatile and reproducible measurements [152,153].  
Interestingly, the two cases of pRCC we observed exhibited a statistically significantly 
fast decrease in contrast intensity compared to the surrounding renal cortex, opposite to what has 
been reported in other studies [145,146]. No significant differences were observed when 
measuring slopes for wash-in and the second phase of wash-out. While it is difficult to suggest 
why pRCC and chRCC display a steep and near constant wash-out, respectively, these may be 
clinically relevant perfusion patterns specific to pRCC and chRCC and should be further 
investigated. Peak-intensity results agreed with previous studies reporting that ccRCCs present as 
hyper-enhancing, while chRCC and pRCC, generally present iso or hypo-enhancing. ccRCC has 
been reported to be a faster growing, metastatic, and more vascular cancer relative to chRCC and 
pRCC, which supports the hypo-enhancing presentation of pRCC on CEUS [154–157].  
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Lu et al. recently published results from a large sample size study using a different 
quantitative approach to differentiate various RCCs. Their TIC analysis consisted of a temporal 
comparison between the lesion and renal parenchymal enhancement that included four distinct 
dynamic vascular patterns: unipolar positive (hyper-enhanced lesion through wash-in/wash-out), 
unipolar negative (hypo-enhanced lesion through wash-in/wash-out), bipolar positive (hyper-
enhanced lesion through wash-in and hypo-enhanced through wash-out), and bipolar negative 
(hypo-enhanced lesion through wash-in and hyper-enhanced through wash-out). They concluded 
that unipolar and bipolar positive flow patterns were indicative of ccRCC and unipolar negative 
was indicative of pRCC and chRCC. While rates of wash-out were not included in their analysis, 
our lesion-to-cortex peak enhancement results agreed with these findings [140].  
This study has several limitations. Our sample size was limited to only 12 patients. Out-
of-plane breathing motion, obstruction of the lesion and parenchyma from rib and bowel 
shadowing, and lack of diagnostic pathology eliminated approximately half of the available data 
sets. For some patients, ideal transducer placement (i.e. wedging under the ribs) was sacrificed 
due to patient comfort, which is a significant limitation of CEUS for focal kidney imaging. We 
believe that standardized CEUS sonography training that describes how to handle the above 
limitations will significantly improve imaging quality. 
A technical improvement made in this study was the use of a stereotactic clamp to hold 
the transducer for the 3-minute clip. This not only alleviated sonographer hand and wrist 
cramping, but maintained steady positioning throughout the clip. This was only feasible if the 
breathing motion was maintained within the imaging plane. For instances where out-of-plane 
movement persisted, manual placement by the sonographer was preferred to track the breathing 
motion. Occasionally, the patient body movement would displace the positioning of the clamp 
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and re-adjusting the position was difficult. While the stereotactic arm by itself may not add 
significant value to the quality of the ultrasound clips, we believe it can be used as an aid in 
positioning of the transducer for longer scans to alleviate sonographer discomfort.  
Of the 12 lesions, there were only 2 pRCC and 2 chRCC, which greatly limited our 
statistical power. Given the small sample size, we were still encouraged by the trends observed 
with the time-to-80% metric and, especially, the peak enhancement ratio, which agreed with 
previous studies. There was only one angiomyolipoma and one oncocytoma, which were not 
included in the final results.  
The TICs in this study were generated from a single cross-section through the kidney that 
captured both the lesion and normal parenchyma. For some patients, anatomic constraints made 
it difficult to orient the transducer directly in the center of the kidney parenchyma to visualize 
wash-in/wash-out in both the cortex and medulla. Kogan et al. reported differences in perfusion 
measurements between parasagittal and coronal planes due to varying amounts of cortical and 
medullary tissue in each plane [158]. While the ROI for the kidney parenchyma was placed over 
the cortex for image analysis on all of the images, the exact position of the ROI undoubtedly was 
inconsistent. The heterogeneity commonly associated with some RCCs is not adequately 
represented in a single cross-section perfusion analysis [159]. Three-dimensional destruction-
reperfusion analysis offers holistic representation of kidney function. Feingold et al. reported 
standard deviations as high as 22% between individual cross-sections of the kidney and 
concluded that the accuracy and repeatability of overall kidney perfusion measurements 
significantly increase with 3-D imaging [160]. Unfortunately, 3-D destruction-reperfusion 
imaging requires a single-array transducer to scan stepwise elevationally and can only capture 
contrast wash-in. The advent of a two-dimensional array transducer capable of high-resolution, 
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real-time 3-D CEUS will allow the calculation of 3-D TICs, which will revolutionize kidney 
perfusion analysis and provide a more precise and accurate representation of the vascularity of 
diseased kidneys and solid kidney lesions. Based on our experience, we recommend a second 
contrast dose to acquire a wash-in/wash-out clip (after waiting the prescribed amount of time 
between doses) with the transducer centered sagittally over the kidney for more consistent 
perfusion measurements of the parenchyma.  
Other limitations of this study are a result of the inherent variability in perfusion imaging. 
Cosgrove et al. describe factors of variability in perfusion imaging, including contrast type, 
circulation profiles of the contrast agent, infusion rate, breathing motion, attenuation, imaging 
settings, etc [161]. Overcoming these sources of variability is critical for the widespread clinical 
use of perfusion imaging. Despite these factors, CEUS has been shown to characterize kidney 
lesions with high sensitivities and negative predictive values (89-100% and 86-100%, 
respectively) [144]. 
 
A.5 Conclusion 
This study suggests that quantitative TIC analysis can be a feasible method for 
identifying subtypes of malignant solid renal masses. We explored different TIC characteristics 
that may be perfusion signatures for clear cell, papillary, and chromophobe RCC subtypes. 
Specifically, peak intensity and time-to-80% on wash-out metrics showed significant differences 
in perfusion patterns between the major RCC subtypes. The bi-phasic wash-out pattern may be a 
clinically important feature that should be further investigated. While very few studies have 
examined the utility of quantitative CEUS for RCC differentiation, there is general agreement 
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with several enhancement metrics. Further validation of these techniques, coupled with the ease 
and safety of CEUS, indicate that CEUS may be a powerful tool for improving diagnostic 
efficacy for RCC clinical management.  
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APPENDIX B: 
Efficient DNA Fragmentation in a Bench-Top Ultrasonic Water Bath Enabled Through the 
Use of Cavitation Enhancing Microbubbles and Nanodroplets3 
 
B.1 Introduction 
Next-generation sequencing is an attractive technology for detecting genetic disorders 
and characterizing the underlying molecular signature of disease to determine therapeutic 
options.  It is not yet, however, a routine diagnostic tool due to a lack of standardization in DNA 
sample preparation, cost, and difficulties in data interpretation [162,163].  Specifically, random, 
unbiased fragmentation of DNA is a bottleneck in next-generation sequencing sample 
preparation pipelines due to serial processing of samples, cost limitations, poor DNA sample 
quality, and lack of reproducibility of fragment size between sample types [164,165].   
 Methods for fragmentation of DNA include enzymatic digestion, nebulization, 
hydrodynamic shearing, and sonication.  Enzymatic digestion using DNase I, MNase, or 
restriction enzymes is very efficient, but introduces an enzyme bias.  Regions of transcriptionally 
silent, tightly packed (heterochromatic) DNA and DNA with high G-C content can be refractive 
to enzymatic digestion and many enzymes only create nicks in the DNA instead of cutting 
completely though both strands [166–172].  The nebulization process shears solubilized DNA by 
forcing it through a pressurized nozzle (atomization).  This method is fast, but requires large 
quantities of DNA and often results in a large distribution in the DNA fragment size and cross-
                                                 
3 This chapter previously appeared as an article in the Public Library of Science. The original citation is as follows:  
Kasoji SK, Pattenden SG, Malc EP, et al. Cavitation Enhancing Nanodroplets Mediate Efficient DNA 
Fragmentation in a Bench Top Ultrasonic Water Bath. PLoS ONE. 2015. 
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contamination between samples [173–175].  Hydrodynamic shearing involves forcing solubilized 
DNA through a mesh.  It has the advantage of rapidly producing small DNA fragments of nearly 
uniform length.  This method, however, is costly and the screen used for shearing is prone to 
clogging and cross-contamination between samples [176,177].  Finally, acoustic sonication uses 
ultrasound to mechanically shear DNA by cavitation.  This method typically produces 
inconsistent results and is time consuming since DNA extracted from cells or tissue must be 
optimized each time to ensure that fragmentation occurs to the desired size range 
[164,178].  Also, similar to enzymatic digestion, heterochromatic DNA or DNA with high G-C 
content are very difficult to shear, which creates a bias toward better shearing efficiency in 
euchromatic and A-T rich regions [164,179–181].  Dedicated high-intensity focused sonicators 
such as a Covaris Adaptive Focused Acoustics™ instrument, or the lower-intensity Diagenode 
Bioruptor™ instrument, produce more consistent DNA fragmentation results than a single probe 
sonication device, however they can be financially inaccessible for many laboratories.    
 We investigated whether a biologically inert agent could be added to DNA samples to 
amplify cavitation in a sonication device and improve the consistency and speed of genomic 
DNA fragmentation.  We initially tested lipid-encapsulated microbubbles, which are bubbles that 
are typically in the 1-10 micron (μm) diameter size range, and have been used in medical 
diagnostics as contrast agents for ultrasound imaging for approximately two decades [182].  The 
highly compressible core of a gas filled microbubble enables it to compress and expand in a 
pressure field in a process called inertial cavitation [183,184].  It has been shown through the use 
of high-speed photography that expansion and compression wall velocity of microbubbles in an 
acoustic field can be on the order of 700 meters per second even at only moderate acoustic 
pressures (1.2 MPa, 2.4 MHz) [185].  At even higher acoustic pressures, which are typical of a 
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commercial sonicator, microbubble cavitation is very unstable and results in a violent collapse, 
locally releasing a great amount of mechanical energy. 
 As an alternative to microbubbles, we designed a novel formulation of phase-change 
nanodroplets [186,187].  These phase-change nanodroplets are composed of a volatile, liquid 
perfluorocarbon core stabilized with a phospholipid monolayer shell with a diameter on the order 
of 200-400 nm [188]. These excipients are biologically inactive when combined with genomic 
DNA samples.  When subject to sufficient acoustic energy and temperature, the nanodroplets 
vaporize into microbubbles that have approximate diameters of 1-5 μm.  The phase-change 
nanodroplets are more stable than microbubbles and require energy to first vaporize and then to 
cavitate, therefore prolonging the cavitation enhancing effect longer than that of bubbles under 
certain conditions.  The increased stability of nanodroplets compared to microbubbles has been 
demonstrated by Sheeran et. al. in an in vivo animal model circulation time study [189]. We 
show that nanodroplets perform as an effective cavitation enhancement agent for the 
fragmentation of gDNA, decreasing sonication time while preserving DNA fragment size 
distribution and yield.  
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B.2 Methods 
B.2.i Genomic DNA preparation 
Genomic DNA was prepared from a 10 mL saturated culture of the Saccharomyces 
cerevisiae wild type haploid strain, BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0).  Genomic 
DNA was purified using the MasterPure™ Yeast DNA Purification Kit (epicenter #MPY80200), 
according to manufacturer instructions.  Quantitation of purified DNA was performed on a 
Qubit® 2.0 Fluorometer. 
 
B.2.ii Microbubble and Nanodroplet Preparation 
Microbubbles consisting of a gas core and an encapsulating lipid monolayer were 
generated by mechanical agitation of a lipid solution in the presence of decafluorobutane (DFB). 
The lipid solution composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) (Avanti 
Polar Lipids, Alabaster, AL, USA) stabilized by 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy (polyethylene-glycol)-2000 (DSPE-PEG2000) (Avanti Polar 
Lipids, Alabaster, AL, USA) in a 9 to 1 molar ratio. The lipid solution was then emulsified in a 
phosphate-buffered saline solution containing propylene glycol (15% v/v) and glycerol (5% v/v) 
with a final lipid concentration of 1.0 mg/mL. 1.5 mL aliquots of the lipid emulsion were 
dispensed into 3 mL vials and sealed with a rubber cap. The air-filled headspace in the vial was 
exchanged with DFB (C4F10, boiling point: -2°C) gas (Fluoromed, Round Rock, TX, USA). 
The vial was vigorously shaken for 45 seconds using a high-speed mixer (Vialmix, Bristol-
Myers Squibb Medical Imaging, North Billerica, MA, USA) to form the microbubble solution. 
The solution contained approximately 1010 bubbles/mL with a diameter of 1.07 ± 0.9 μm, 
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measured with an Accusizer 780 (Particle Sizing Systems, Santa Barbara, CA, USA).  
 Nanodroplets were formed by cooling and compressing the microbubble solution to 
induce a gas-to-liquid phase transition of the DFB gas.  Dry ice was used to cool approximately 
100 mL of N-propanol to -9° C in a beaker. A 20-gauge needle connected to a fully-drawn 60 
mL syringe was inserted into the DFB-headspace through the rubber cap of the vial. The vial was 
then submerged into the 2-propanol and swirled while simultaneously increasing the pressure 
inside of the vial by depressing the syringe plunger, eventually condensing the bubbles into 
droplets. The nanodroplet solution was stored at -20° C when not in use. 20 μL of nanodroplets 
were dispensed in each DNA sample for sonication. 
 
B.2.iii DNA Fragmentation: Covaris E110 Sonicator 
Five μg of BY4741 gDNA was added in duplicate to either Covaris microTUBEs 
(#520045), or borosilicate glass vials in a final volume of 100 μL in TE (10 mM Tris-HCl, pH 
8.0, 1 mM EDTA).  Ten μL of nanodroplets was added to the borosilicate glass vials.  Sample 
tubes were submerged up to the cap in a water bath and sonicated for 2 minutes each at 20% duty 
cycle, Intensity 8, and 200 cycles per burst.  After fragmentation, 20 μL of DNA was combined 
with 10X loading buffer (50% glycerol with Orange G and SYBR green) and loaded onto a 1.5% 
agarose gel and subjected to gel electrophoresis.  For high throughput sequencing preparation, 
each sample was concentrated in a Zymo Research ChIP DNA Clean & Concentrator column 
(#D5201), followed by quantitation on a Qubit® 2.0 Fluorometer.  DNA fragment quality and 
size was assessed using an Agilent D1000 ScreenTape system. 
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B.2.iv DNA Fragmentation: Branson Sonifier Bath 
Five μg BY4741 gDNA was added in quadruplet to 0.2 mL PCR strip tubes (Genesee 
Scientific #27-104) in a 150 μL volume in TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA).  Ten μL 
of microbubbles or nanodroplets were added to each of two of the samples.  The samples were 
placed in a linear acrylic tube holder (0.5” spacing) and positioned in the center of the ultrasonic 
bath such that the sample tubes were submerged up to the cap in water.  The water bath was 
either cooled to 3-4° C using a circulating refrigerated bath chiller followed by sonication for 5 
minutes, or chilled ice water was added just prior to sonication.  Following fragmentation, 20 μL 
of DNA was combined with 10X loading buffer (50% glycerol with Orange G and SYBR green) 
and loaded onto a 1.5% agarose gel and subjected to gel electrophoresis.  Densitometry was 
performed using Image J software.  For high throughput sequencing preparation, each sample 
was concentrated in a Zymo Research ChIP DNA Clean & Concentrator column (#D5201), 
followed by quantitation on a Qubit® 2.0 Fluorometer.  DNA fragment quality and size was 
assessed using an Agilent D1000 ScreenTape system. 
 
B.2.v Next-generation Sequencing 
Yeast gDNA samples sonicated in the Covaris E110 were prepared using Kapa DNA 
Library Prep Kit for Illumina (#8234). Libraries were prepared using both agarose gel size 
selection (Sage Science Pippin Prep Targeted DNA Size Selection System) and magnetic bead 
selection (Magbio HighPrep™ PCR beads (#AC-60500), with 0.45 and 0.2 ratios for the first 
and second step of size selection, respectively) to ensure that the size selection method did not 
influence sequencing result comparison.  
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Yeast gDNA samples fragmented in the ultrasonic bath were prepared using the Illumina 
TruSeq Nano DNA LT Sample Preparation Kit (#FC-121-4001).  Each sample was prepared 
with either 200 ng or 100 ng of DNA and size-selected using magnetic beads as described.  
 Following preparation, all libraries were quantified using a Qubit® 2.0 
Fluorometer.  DNA fragment quality and size was assessed using Bio-Rad Experion™ 
Automated Electrophoresis System.  Sequencing data have been deposited to the BioProject 
database (National Center for Biotechnology Information), BioProject accession PRJNA284931.  
 
 
B.3 Results and Discussion 
B.3.i Nanodroplets are a shelf-stable agent that perform better than microbubbles for DNA 
fragmentation 
Microbubbles were initially evaluated as a cavitation enhancement agent in the Covaris 
E110 sonicator.  We observed a significant increase in fragmentation of DNA within 300-500 bp 
(as illustrated by the % band density of the gels outside the desired bp range, Figure B.1) 
Microbubbles, however, are rapidly fragmented in a high amplitude acoustic field (half-life in 
the order of seconds) so their effective cavitation enhancement was only 5-10 seconds with the 
given acoustic parameters.  We hypothesized that by condensing microbubbles to form 
nanodroplets, we could control the release of microbubbles therefore sustaining the cavitation 
enhancement.   
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Figure B. 1.  Analysis of the fragmented DNA products following focused-wave sonication of 
purified genomic DNA. Gel electrophoresis (A) demonstrated DNA fragments in the desired 
200-500 base pair (bp) range after 30 (lanes 6-8) and 60 seconds (lanes 12-14) of sonication in 
the presence of microbubbles (microbubble). In contrast, few fragments of this size were 
recovered in the absence of microbubbles out to 1 minute (lanes 3-5 and 9-11). The normalized 
average intensity plot profiles for each test condition (B) were graphed as a function of bp 
length, with the desired range shaded gray.  (C) Densitometry analysis indicates that DNA 
fragmentation is centered in the 200-500 bp range for samples sonicated in the presence of lipid-
encapsulated microbubbles.  Error bars represent the standard deviation for 3 biological 
replicates with 3 technical replicates each.   
 
 Microbubbles were produced through vigorous mechanical agitation of a lipid solution 
inside a 3 mL vial, followed by simultaneously cooling and increasing ambient pressure of the 
microbubble solution to condense the bubbles into nanodroplets (Figure B.2A).  A persistence 
study was performed to test the half-life of microbubbles versus nanodroplets using the 
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ultrasonic bath, showing that nanodroplets persist much longer with acoustic parameters kept 
constant (Figure B.2B).  In addition, we demonstrated that nanodroplets have excellent shelf 
stability; they can be stored at -20°C with no loss of performance following multiple freeze-thaw 
cycles (Figure B.3A).    
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Figure B. 2. Nanodroplets persisted in solution longer than microbubbles. A) Flow chart 
outlining method for production of nanodroplets. B) A persistence study was performed in the 
ultrasonic bath to compare nanodroplets and microbubbles. An Accusizer particle sizing system 
(Particle Sizing Systems, Port Richey, FL) was used to measure the microbubble and 
nanodroplet concentrations at specific time points between 0 and 300 seconds (5 minutes). 
Nanodroplets maintained between 10–20% of their initial concentration as far out as 3 minutes 
into the sonication treatment, while the microbubble concentration dropped to 10% after 1 
second. 
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B.3.ii DNA fragmented in the presence of nanodroplets is consistent with DNA fragmented 
by a commercially available method 
DNA fragmentation was initially compared with or without nanodroplets in the 
commercially available Covaris E110 sonicator.  Borosilicate glass vials produced a smaller 
average fragment size within a given sonication time compared to plastic PCR tubes, so all 
further experiments in this instrument were performed in the borosilicate glass Covaris 
microTUBE (Figure B.3B, compare lanes 1-3 to lanes 4-6).  The Covaris microTUBE contains a 
hydrophobic polymer rod with small pores that enucleate gas bubbles when exposed to acoustic 
energy [190].  Comparisons were made between duplicate samples of the microTUBE with the 
rod, and the microTUBE with nanodroplets (Figure B.4A).  Genomic DNA purified from the 
Saccharomyces cerevisiae strain, BY4741, was used for this study as the small genome size 
allowed for high density sequencing coverage.   
 
Figure B. 3. Nanodroplets are an effective cavitation agent for use in DNA fragmentation.  A) 
The effectiveness of nanodroplets as a cavitation enhancement agent after multiple freeze-thaw 
cycles was tested.  DNA ladder size is indicated in base pairs.  Input is DNA prior to sonication 
with nanodroplets.  B) Comparison of DNA fragmentation efficiency after two minutes in glass 
(Lanes 1-3) versus plastic (Lanes 4-6) tubes in the Covaris E110 sonicator.  The addition of 
nanodroplets to Covaris microTUBES produces a DNA fragment size distribution comparable to 
the microTUBES with a rod (compare Lanes 1 and 3).  DNA fragmented in glass microTUBES 
had a smaller DNA size distribution compared to plastic 0.2 mL PCR tubes (compare Lanes 3 
and 5-6).  DNA ladder size is indicated in base pairs.  
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Figure B. 4. Saccharomyces cerevisiae genomic DNA (BY4741) fragmented with nanodroplets 
in a commercial sonicator is comparable in quality to DNA fragmented using a commercial 
method.  A) Flow chart outlining method for comparing DNA fragmentation methods.  B-C) 
DNA fragment size distribution was determined on an Agilent D1000 ScreenTape system.  B) 
False gel picture showing DNA fragment size distribution in base pairs for samples fragmented 
in the Covaris E110 sonicator.  Purple bars indicate the upper (1,500 bp) molecular weight 
marker and green bars indicate the lower (25 bp) molecular weight marker in each lane.  C) 
Traces for DNA samples in microTUBES with the rod (left panel) or microTUBES with 
nanodroplets (right panel) that were subjected to sequencing.  Average size is indicated in base 
pairs (bp).  DNA size markers are denoted by Upper and Lower.  D) Traces showing similar size 
distribution of DNA after sequencing library preparation. Average size is indicated in base pairs 
(bp).  DNA size markers are denoted by Upper and Lower.  E) Mapping sequencing reads to the 
Saccharomyces cerevisiae (S288c) reference genome is comparable in detection of single 
nucleotide variations and indels.  Abundance and profile of relative errors in sequencing reads 
does not indicate a difference in the presence of error bias in the data. 
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Following two minutes of sonication, the average DNA fragment size was comparable 
between the microTUBE and nanodroplet samples (Figure B.4B, Figure B.4C).   To confirm that 
the DNA fragmented in the presence of nanodroplets was suitable for downstream applications, 
we subjected these samples to next-generation sequencing.  Following library preparation, no 
difference in quality and profile was noted between the two samples (Figure B.4D) or between 
duplicate samples. Both average fragment size and the fragment distribution profiles were 
similar and depended on the chosen size selection method and not sonication method (Table 
D.2). 
  
 128 
  
 
 Sequencing reads were mapped to the Saccharomyces cerevisiae S288C reference 
genome, from which the BY4741 strain used in this study was derived [191].  Samples 
fragmented in the presence of nanodroplets showed no appreciable difference in mapped reads, 
Figure B. 5. The addition of nanodroplets allows genomic DNA fragmenation in an ultrasonic water 
bath.  A) Schematic showing the ultrasonic bath used for sonication.  Samples are immobilized in the 
water bath using a stand with a tube rack attached.  The circulating water chiller is optional.  Water 
chilled to four degrees Centigrade can be added just prior to sonication, with no loss in DNA 
fragmentation efficiency.   B) A time-titration was performed with samples with and without 
nanodroplets. Following fragmentation, samples were run on a 1.5% agarose gel and visualized using 
SYBR green.  DNA ladder sizes are indicated in base pairs.  C) Arrangement of DNA samples 
fragmented in the ultrasonic bath with and without samples to produce D) an acoustic field map of the 
bath. The fragmentation ability (base pair size) is visualized with the color bar, where red indicates 
complete fragmentation in the 200-500 bp range. 
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detection of single nucleotide variations and insertions and deletions (indels), or error bias in the 
data (Figure B.4E) compared to samples fragmented in the microTUBEs.  Thus, genomic DNA 
fragmented in the presence of nanodroplets is consistent with a commercially available method. 
 
Figure B. 6. DNA fragmentation in an ultrasonic water batch compared to a commercially 
available device. A) Flow chart outlining method for comparing DNA fragmentation methods. 
 
B.3.iii The addition of nanodroplets permits DNA fragmentation in a bench top ultrasonic 
water bath 
Most commercially available sonication devices are low thoughput, sonicating only a 
single sample at a time.  Since gDNA fragmentation with nanodroplets was effective in a 
commercially available sonicator, we tested the performance of nanodroplets in a standard 
laboratory ultrasonic water bath with the aim of increasing sample throughput, and negating the 
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need for specialized equipment.   
 A Branson 2510 Ultrasonic Cleaning Bath was converted to a gDNA sonicator by 
installing a simple custom tube holder to submerge sample vessels at desired positions in the 
bath. To maintain the temperature conditions of current DNA fragmentation methods, water was 
pre-chilled to 4° C and added to the ultrasonic bath. Chilled water could also be circulated using 
a refrigerated water chiller (Figure B.5A).  The operating level of the ultrasonic bath was 
demarcated by the manufacturer at double the operating wavelength of the acoustic field in water 
at room temperature (25°C).  To maintain constant acoustic parameters, we adjusted the water 
level according to the wavelength change of the acoustic field in water at 5°C.  Sonication time 
was optimized to five minutes in thin walled PCR tubes (Figure B.5B).  These tubes were 
selected because the thin wall was less likely to interfere with the acoustic field, and they are 
inexpensive and readily available from a number of commercial vendors.  An acoustic field map 
achieved by sonicating a five-by-five array of DNA samples (Figure B.5C) determined that the 
most consistent gDNA fragmentation occurred in the central region of the bath (Figure 5D), so 
samples were immobilized within this area using a custom sample holder.  The holder for these 
studies consisted of a single row of 14 samples with 0.5 inch spacing. In future studies, spacing 
will be further optimized to maximize the number of samples that can be fragmented at once. 
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Figure B. 7. Saccharomyces cerevisiae genomic DNA (BY4741) fragmented with nanodroplets 
in an ultrasonic water bath is comparable in quality to DNA fragmented in a commercially 
available device.  (A) Agilent D1000 ScreenTape data showing size distribution of DNA 
fragmented in tubes without (left panel) or tubes with nanodroplets (right panel).  Average size is 
indicated in base pairs (bp).  DNA size markers are denoted by Upper and Lower.  (B) False gel 
picture indicating that DNA fragmented without nanodroplets had an average fragment size 
>1,500 bp.  Purple bars indicate the upper (1,500 bp) molecular weight marker and green bars 
indicate the lower (25 bp) molecular weight marker in each lane.  (C) Size distribution of DNA 
after sequencing library preparation.  Average size is shown in base pairs (bp).  DNA size 
markers are denoted by Upper and Lower.  (D) Mapping sequencing reads to the Saccharomyces 
cerevisiae (S288c) reference genome is comparable in detection of single nucleotide variations 
and indels in Figure B.4E.  Abundance and profile of relative errors in sequencing reads does not 
indicate a difference in the presence of error bias in the data compared to data in Figure B.4E. 
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To confirm that the DNA fragmented in the ultrasonic water bath could be used for next-
generation sequencing, fragmentation of BY4741 yeast gDNA was performed in duplicate in the 
presence and absence of nanodroplets (Figure B.6).  In the absence of nanodroplets, the average 
DNA fragment size was >1,500 bp, a size not suitable for library preparation (Figure B.7A, 
B.7B, Table D.2).  Samples with nanodroplets had an average fragment size of <250 bp before 
library preparation (Figure B.7A, B.7B), and an average size of 500 bp after library preparation 
(Figure B.7D, Table D.2), which was comparable to data obtained from fragmentation in the 
Covaris (Figure B.4C, B.4D, Table D.2).  After sequencing, the duplicate samples fragmented in 
the presence of nanodroplets showed no appreciable difference in mapped reads, detection of 
single nucleotide variations and indels, or error bias in the data (Figure B.7E).  Therefore, 
cavitation enhancement by nanodroplets in a standard laboratory ultrasonic water bath produced 
fragmented gDNA that was comparable to DNA obtained from sonication in a commercially 
available device.   
 The sonication methods that are employed by the Covaris and the ultrasonic water bath 
are different with respects to the acoustic frequency used and the distribution of the acoustic 
field. The Covaris uses a spherically focused 1 MHz ultrasound transducer which produces a 
very tight (~2 mm) focus. The ultrasonic water tank uses two heavy-duty 40 kHz sandwich type 
transducers that produce a broad acoustic field within the tank, which is amplified by standing 
waves created by reflections from the water-air interface and the sides of the tank. DNA can be 
fragmented using both systems, through the combination of cavitation mechanisms and high 
microscopic fluid flow (Figure C.4). The overall intensity of the acoustic field in the ultrasonic 
water tank is less than the acoustic intensity at the focal spot of the Covaris transducer, however 
the probability threshold for cavitation events increases with decreasing frequency 
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[187].  Furthermore, the addition of the nanodroplets further enhances the cavitation effect. The 
ultrasonic tank possesses the advantage of increasing the number of cavitation events and having 
a larger effective acoustic field area allowing greater number of samples to be treated 
simultaneously (Figure B.5D). 
 
B.4 Conclusion 
We have demonstrated that fragmentation of gDNA in the presence of nanodroplets does 
not require specialized equipment, can be performed for multiple (up to 14) samples 
simultaneously in five minutes, and produces high quality, fragmented DNA for next-generation 
sequencing.  Phase change nanodroplets are produced using a simple method and can be stored at 
-20°C for extended periods of time, withstanding multiple freeze-thaw cycles. The use of this 
cavitation enhancement agent in combination with a standard laboratory ultrasonic bath is a 
useful and cost-effective method for academic institutions and research laboratories that do not 
have access to specialized sonication devices, and provides new accessibility and improved 
efficiency for a crucial step in next-generation sequencing. 
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APPENDIX C: 
Supplementary Figures 
Figure C. 1 
 
Figure C. 1. Growth curves of PN and vessel tortuosity metrics (SOAM, DM, and TCM). No 
statistically significant differences in any metrics were observed. Increased PN is observed in 
partial responders, however the mean values for untreated controls and complete responders are 
inconsistent.  
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Figure C. 2 
 
Figure C. 2. Differences in SOAM, DM, and TCM between partial responders and complete 
responders at the final measurement time point when we clearly observe statistical differences 
between the two groups using TV. No statistical differences were found between response 
groups.  
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Figure C. 3 
 
Figure C. 3. Transmit waveform centered at 3.5 MHz. and frequency spectrum of the RMV 
probe, as a comparison to the DF-TRUS and DP-DF transducers. The pulse length is 
considerably shorter than the DF-TRUS probe.  
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Figure C. 4 
 
Figure C. 4. The starch-iodine test was performed to confirm the presence of cavitation. If 
cavitation is present, the Starch-KI solution turns from clear to blue. Reactive oxygen species 
that form during a violent cavitation event transform dissolved iodide ions into iodine. Iodine 
then conforms to the starch molecule and results in a visible blue color. The results from the 
Covaris and the ultrasonic bath are displayed in a dot blot array. In both the Covaris and the 
ultrasonic bath, vials with no rod or nanodroplets showed minimal fragmentation. 
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Figure C. 5 
 
Figure C. 5. CTR vs. Imaging Depth in an attenuating phantom of the DF-TRUS and DP-DF 
transducers. The CTR drastically decreases past 10 mm for the DF-TRUS probe.  
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APPENDIX D: 
Supplementary Tables 
 
Table D. 1. Summary of SNR and CTR values for all probes for comparison. 
 DF-TRUS DP-DF RMV EV-8C4 
SNRdB (dB) 19.25 24.05 ~ ~ 
SNRImg 0.86 3.66 2.6 1 
CTRdB (dB) 6.9 16.6 ~ ~ 
CTRImg 0.26 1.1 4.5 1 
 
 
Table D. 2. Preparation methods for sequencing libraries. 
Sonication 
Device 
Sample ID Average 
Fragment 
Size (bp) 
Concentration 
(ng/μL) 
Size 
Selection 
Method 
Average 
Fragment Size 
After Library 
Preparation (bp) 
Covaris microTUBE 
with rod 
265 7.26 Pippin 
Prep 
480 
Covaris microTUBE 
with rod 
267 20.4 Bead 440 
Covaris microTUBE 
with 
nanodroplets 
259 12 Pippin Prep 470 
Covaris microTUBE 
with 
nanodroplets 
294 35.8 Bead 420 
Ultrasonic 
Bath 
PCR tube no 
additive 
>1,500 N/A N/A N/A 
Ultrasonic 
Bath 
PCR tube no 
additive 
>1,500 N/A N/A N/A 
Ultrasonic 
Bath 
PCR tube with 
nanodroplets 246 
24.6 Bead 503 
15.6 Bead 515 
Ultrasonic 
Bath 
PCR tube with 
nanodroplets 214 
32.2 Bead 497 
9.4 Bead 482 
Table D. 2. The average fragment size for each sample is shown before and after library 
preparation. Size selection methods include magnetic bead (Bead) and automatic gel size 
selection (Pippin Prep, Sage Science). Samples with variable concentrations produced libraries 
with a similar fragment size. 
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